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INTRODUCTION
Protein kinases comprise a large enzyme family in eu-
karyotes and prokaryotes. Protein kinases catalyze the transfer
of the terminal phosphoryl group of ATP to their specific
protein substrates. It has been recognized for 50 years that
protein phosphorylation regulates many aspects of cellular
function, such as metabolism, division, movement, survival,
and death. Thus, any process that disrupts normal phosphory-
lation can disrupt cell function and cause disease (61). Con-
served sequence motifs have allowed the identification of 518
protein kinases within the human genome, with these being
grouped into 20 families based on sequence similarities (205).
Additional analyses are being increasingly undertaken with a
range of eukaryotes and prokaryotes, revealing striking con-
servation of some protein kinases across a range of organisms
as well as protein kinase family members specific to particular
organisms (42, 49, 112, 314).
The c-Jun N-terminal kinases (JNKs) are members of a
larger group of serine/threonine (Ser/Thr) protein kinases
known as the mitogen-activated protein kinase (MAPK) fam-
ily. The MAPK family is one subgroup of the CMGC class of
protein kinases (where CMGC is the class name derived from
the major kinase members of this class, namely, cyclin-depen-
dent kinases [CDKs], MAPKs, glycogen synthase kinase 3
[GSK3], and casein kinase 2-related protein kinases). Within
the classification of all protein kinases, the CMGC class rep-
resents one of the three major protein kinase classes, in addi-
tion to classical Ser/Thr kinases and tyrosine (Tyr) kinases
(122). The JNKs act within a protein kinase cascade (Fig. 1A
and B). They are themselves activated by dual phosphoryla-
FIG. 1. Overview of the JNK pathway. (A) The classical JNK pathway was considered to be activated following the exposure of cells to
extracellular stresses, such as UV irradiation, hyperosmolarity, and heat shock. Subsequently, JNK activation was also demonstrated following the
exposure of cells to some proinflammatory cytokines, including TNF- and interleukin-1 (IL-1), as well as following the activation of Toll-like
receptors. The pathway has been shown to involve the activation of various small G proteins and the engagement of adaptor proteins, followed
by a protein kinase cascade. This cascade includes various members of the MAPK kinase kinase family (such as MEKKs, hematopoietic progenitor
kinase [HPK], the mixed-lineage kinases [MLKs], transforming growth factor -activated kinase [TAK], and apoptosis signal-regulating kinase
[ASK]) and the MAPK kinases MKK4 and MKK7 and leads to JNK activation. (B) Any disruption of protein processing and folding within the
ER leading to ER stress can also activate JNKs, and this is mediated by an ER stress transmembrane sensor protein kinase (IRE), the adaptor
protein TNF receptor-associated factor 2 (TRAF2), and the upstream kinase ASK1. (C) In mammalian systems, there are three genes that encode
the JNKs, namely, jnk1, jnk2, and jnk3. The alternative names for these JNK isoforms are provided, alongside information on their splice forms
and positions on the mouse chromosomes. (D) Linear representation of the JNK11 protein highlighting conserved features of protein kinases
such as the JNKs, with 11 regions of sequence similarity (I to XI), as originally identified by Hanks and colleagues (123). In addition, the positions
of two residues in the “activation/phosphorylation loop” are indicated (**).
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tion, by the MAPK kinases MKK4 and MKK7, on a specific
Thr and a specific Tyr in a typical Thr-X-Tyr motif within their
“activation/phosphorylation loop” sequences (for a review, see
reference 73).
The diversity of mediators upstream of MKK4 and MKK7
(Fig. 1A) may allow JNK pathway activation by a range of
external stimuli (for a review, see reference 73). As studies of
JNK pathways have progressed, the range of initiating signals
has been expanded to include a diversity of stimuli. Of partic-
ular interest is the activation of the JNK pathway following the
exposure of cells to a range of proinflammatory cytokines, such
as tumor necrosis factor- (TNF-) and interleukin-1 (for a
review, see reference 81). Furthermore, the JNK pathway is
activated in the innate immune response following the activa-
tion of various members of the Toll-like receptor family by
invading pathogens (e.g., see references 13, 15, 178, 182, 216,
259, and 272) (Fig. 1A). The JNK pathway therefore appears
to act as a critical intermediate in signaling in the immune
system (81). As also shown in Fig. 1B, there are increasing links
between the endoplasmic reticulum (ER) stress response and
JNK activation (for a review, see reference 317). This provides
at least one mechanism of activation of JNKs following the
sensing of internal stress events, such as protein misfolding.
There is also an increasing body of literature showing that JNK
activation follows bacterial, fungal, prion, parasitic, or viral
infections. Under these circumstances, JNK activation may
influence important cellular consequences, such as alterations
in gene expression (1, 53, 59, 162, 167, 176, 199, 294, 325, 326,
346), cell death (58, 89, 137, 139, 169, 193, 243, 293), viral
replication, persistent infection or progeny release (215, 224,
251, 260), or altered cellular proliferation (178). The exact
mechanism of JNK activation under each of these circum-
stances remains to be elucidated fully, although there may be
involvement of Toll-like receptors, direct pathway modulation
through interaction with upstream protein regulators, or the
activation following an ER stress response (79, 87, 110, 124,
143, 191, 253, 261, 279, 294, 312).
Originally identified as stress-activated protein kinases
(SAPKs) in the livers of cycloheximide-challenged rats (177),
the subsequent purification, cloning, and naming of the JNKs
have emphasized their ability to phosphorylate and activate the
transcription factor c-Jun (77, 222, 257). The JNK-mediated
phosphorylation of both Ser63 and Ser73 within the transacti-
vation domain of c-Jun (Table 1) potentiates its transcriptional
activity through the loss of repression mediated by an inhibi-
tory complex associated with histone deacetylase 3 (316).
Other events that follow c-Jun phosphorylation include its
increased interaction with other binding partners, such as
the transcription factor TCF4 or the E3 ubiquitin ligase
Fbw7 (240, 241). The importance of c-Jun phosphorylation
has been emphasized in studies of transgenic mice express-
ing the c-Jun mutant c-Jun Ser633Ala Ser733Ala, which
lacks the two major sites for phosphorylation by JNK (22,
23, 72, 130, 150, 311). Increasing attention has been directed
towards JNK as an activator of a wide range of c-Jun-
dependent events, including apoptotic cell death and onco-
genic transformation (22, 23, 188).
The mammalian JNKs are encoded by three distinct genes
(Jnk1, Jnk2, and Jnk3) (Fig. 1C). Additional complexity is gen-
erated by alternative splicing, which results in up to 10 different
protein products varying in size from 46 kDa to 55 kDa (117;
for a review, see reference 17).
Specifically, four splice forms arise from the Jnk1 gene, four
arise from the Jnk2 gene, and two arise from the Jnk3 gene
(Fig. 1C). While JNK1 and JNK2 are expressed in a variety of
tissues, JNK3 expression is restricted primarily to the brain,
heart, and testes (207, 225). This tissue-specific distribution,
particularly for JNK3 expression, has led to the idea that dif-
ferent isoforms may perform different cellular roles. This has
been explored further through studies in which the effects of
deletions of the Jnk genes alone and in combination have been
evaluated (for a review, see reference 30). Later sections of this
review explore this isoform specificity further.
The primary structure of JNK11 is illustrated in Fig. 1D,
which highlights the conserved features of the protein kinase
domains of the JNKs. The subdomain numbering system
shown in Fig. 1D denotes conserved sequence regions I to XI,
originally defined by Hanks and colleagues for all protein ki-
nases (123). Crystal structures were subsequently determined
for JNK3 in the presence of an ATP analogue (327) and
several small-molecule inhibitors (273) and for JNK1 in the
presence of small-molecule ATP-competitive inhibitors (195,
290) and an inhibitory peptide from the JNK-interacting pro-
tein 1 (JIP1), with and without a small-molecule ATP-compet-
itive inhibitor (129). Examples of these structures are shown in
Fig. 2.
As expected, the structures of JNK1 and JNK3 are similar to
each other and to those of other MAPKs. They have the typical
eukaryotic protein kinase fold, as shown in Fig. 2A, comprising
two domains or lobes, with an N-terminal domain rich in
-structure (residues 9 to 112 and 347 to 363 in JNK1 and
residues 45 to 149 and 379 to 400 in JNK3) and a C-terminal
domain rich in -helices (residues 113 to 337 in JNK1 and
residues 150 to 374 in JNK3). The JNK C-terminal domain has
an insertion typical of the MAPKs, and this is 12 residues
longer in JNKs than in the related MAPKs extracellular signal-
regulated kinase 2 (ERK2) and p38. These two domains are
connected by two peptide segments, and based on structures of
other protein kinases in complex with peptide substrates (34,
140, 171, 198, 335), the peptide substrates for JNK are ex-
pected to bind into the groove between the two lobes of JNK.
The ATP molecule also binds near the domain interface. All of
these structures have been determined for the inactive non-
phosphorylated forms of JNK. It is expected that subtle but
important changes in structure will accompany activation, as
seen for the related MAPK ERK2 (183). The nonphosphory-
lated JNK structures are inactive due to the misalignment of
the catalytic residues accompanying the relative rotation of the
two domains and the obstruction of the active site by the
“activation loop.” In contrast, the ATP-binding site is well
formed in JNK structures.
In this review, an overview of the substrates of JNK is pre-
sented, beginning with a consideration of the nuclear substrates of
JNK that have now been described, in addition to c-Jun. We
consider the phosphorylation of 26 nuclear substrates of JNKs
(Table 1) and discuss how phosphorylation alters their functions.
Many of these nuclear proteins are transcription factors, and
therefore their phosphorylation by the JNKs can mediate actions
via a direct link to changes in gene expression following the
exposure of cells to a range of cytokines and stress stimuli. How-
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TABLE 1. Summary of nuclear substrates of JNKs and their phosphorylated sequencesa
Nuclear protein (function [GenBank accession no.]) Phosphorylation sitesequence(s) Reference(s)
c-Jun (transcription factor [AAA37419]) D-L-L-T-S63-P-D-V-G 77, 230
L-K-L-A-S73-P-E-L-E
H-I-T-T-T91-P-T-P-T
JunB (transcription factor [NP_032442]) I-T-T-T-T102-P-T-P*-P 190
T-T-T*-P-T104-P-P-G-Q
JunD (transcription factor [CAA40010]) G-L-L-A-S90-P-D-L-G 339
L-K-L-A-S100-P-E-L-E
L-V-T-T-T117-P-T-S-T
ATF2 (transcription factor [AAH26175]) V-A-D-Q-T69-P-T*-P-Tb 118, 197
D-Q-T*-P-T71-P-T-R-Fb
JDP2 (transcription factor [NP_446346]) D-S-V-R-T148-P-S-E-S 155, 156
Elk-1 (transcription factor [AAH56150]) W-S-T-L-S383-P-I-A-P 321, 337
I-A-P-R-S389-P-A-K-L
Net (transcription factor [CAA83676]) V-S-S-V-S239-P-S-S-S 86
S-S-S-R-S245-P-S-L-S*b
S*-P-S-L-S249-P-D-S*-Pb
L-S*-P-D-S252-P-L-P-Sb,c
HSF1 (transcription factor [NP_005517]) G-R-P-P-S363-P-P-P-T 65
c-Myc (transcription factor [AAA20942]) T-P-P-L-S62-P-S-R-R 6
R-G-L-C-S71-P-S-Y-V
p53 (transcription factor [AAA59988]) P-A-A-P-T81-P-A-A-Pd 41, 95
NFATc3 (transcription factor [P97305]) E-S-S-L-S163-P-S*-P-Ab 57
S-L-S*-P-S165-P-A-S-Sb
NFATc1a (transcription factor [NP_765978]) P-A-L-E-S117-P-R-I-E 56
P-S-C-L-S172-P-A-S-S
NFATc2 (transcription factor [NP_036472]) R-I-E-I-T116-P-S-H-E 248
FOXO4 (transcription factor [P98177]) K-A-L-G-T447-P-V-L-T*b 90
T*-P-V-L-T451-P-P-T-Eb,e
STAT3 (transcription factor [NP_998824]) D-L-P-M-S727-P-R-T-L 349
STAT1 (transcription factor [NP_009330]) L-L-P-M-S727-P-E-E-F 352
Pax2 (transcription factor [CAA39302]) Not determinedf 43
P-S-T-A-S170-P-P-V-S
L-P-A-L-T296-P-G-L-D
A-L-L-S-S296-P-Y-Y-Y
TCF1 (transcription factor [NP_002639]) G-G-E-P-S232-K-K-R-K 154
R-T-S-F-T242-P-Q-A-I
Peroxisome proliferator-activated receptor 1 (nuclear hormone
receptor [AAA19971])
V-E-P-A-S82-P-P-Y-S 45
Glucocorticoid receptor (nuclear hormone receptor [AAA41203
and NP_000167])
E-N-L-L-S246-P-L-A-Gg 37, 266
N-C-L-L-S226-P-L-A-Gg 147
Retinoic receptor RAR (nuclear hormone receptor [NP_000955]) S-Y-T-L-T181-P-E-V-G 283
P-G-S-C-S445-P-S-L-S
P-A-T-H-S461-P
Retinoic receptor RXR (nuclear hormone receptor [P28700 and
NP_002948])
S-T-L-S-S61-P-I-N-Gh 2
S-V-I-S-S75-P-M-G-P
S-V-P-T-T87-P-T-L-G
L-N-P-S-S265-P-N-D-P
M-A-A-P-S32-L-H-P-S 204
Nur77 (orphan receptor [P12813]) Not determinedi 121, 174
P-S-P-S-T145-P-N-F-Q
Androgen receptor (nuclear hormone receptor [AAA51729]) S-S-T-T-S650P-T-E-Ej 109
hnRNP-K (NP_112553) L-I-S-E-S216-P-I-K-G 119
I-D-T-W-S353-P-S-E-W
TIF-IA (Pol I-specific transcription factor [AJ272050]) Y-V-P-S-T200-P-W-F-L 211
a A range of nuclear proteins that are predominantly transcription factors and nuclear hormone receptors have been demonstrated to be substrates for JNK-mediated
phosphorylation. This table summarizes these proteins and provides sequence information on the phosphorylation sites identified. For each phosphorylation site, a
nine-amino-acid sequence surrounding the residue that is phosphorylated is provided. As shown, multiple sites of phosphorylation have been identified for many nuclear
proteins.
b In the indicated sequences, S* or T* represents Ser or Thr residues that have also been shown to be phosphorylated by JNKs, showing that JNKs may phosphorylate
a number of closely spaced residues. It remains to be determined whether there is any requirement for hierarchical phosphorylation of these substrates by JNKs.
c In the Phospho.ELM database of phosphorylation sites (http://phospho.elm.eu.org/), Net is listed as Elk3. However, the site of phosphorylation that is attributed
to JNK (i.e., Ser 357) has been demonstrated as a site of phosphorylation for kinases downstream of MKK6 and Ras, not for those downstream of the JNK activator
kinases.
d Ser34 was shown to be phosphorylated by JNK, but this residue is found in murine p53 and not conserved in human p53 (219).
e In the protein sequence, the phosphorylated residues correspond to Thr451 and Thr455.
f In the protein sequence, there are two S-P and three T-P motifs. The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus
(Scansite [329] score, 0.2074).
g The sequences are rat and human sequences, respectively (37, 147, 266).
h The first four sequences are murine, and the last sequence is human (2, 204).
i In the protein sequence, there are 11 S-P and 2 T-P motifs. The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus (Scansite
[329] score, 0.13827).
j In the protein sequence, the phosphorylated residues correspond to Ser648.
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ever, JNK substrates in other cellular compartments have also
been described, and the effects of phosphorylation of an addi-
tional 26 nonnuclear substrates of JNKs are discussed in turn (see
Table 3). These substrates provide a link to a wide range of
cellular functions, including cell death and cell movement, as well
as allowing for modulation of other signaling events in the cell.
We summarize the known effects of phosphorylation on these
nuclear and nonnuclear substrates in Fig. 3. This summary shows
that JNK-mediated phosphorylation may either enhance or in-
hibit the activities of its substrates and that, in some cases, the
phosphorylation-dependent changes are more complex and in-
volve changes in protein binding and/or localization in the cell.
Therefore, the functional effects of phosphorylation following
JNK activation must always be specifically tested. Lastly, the de-
terminants of the substrate specificity of JNKs are examined in
greater detail, and the effects of JNK-mediated phosphorylation
are discussed within the broader context of signal transduction
cross talk, integration, and diversification. This analysis reveals
the complexities of signal transduction and the new challenges
faced in evaluation of signal transduction pathways and their
consequent effects.
JNK-MEDIATED PHOSPHORYLATION OF THE
ARCHETYPICAL SUBSTRATE c-Jun
Studies on the phosphorylation of c-Jun and related tran-
scription factors have provided many useful insights into the
mechanisms of JNK-mediated phosphorylation (117, 152). The
phosphorylation sequences in c-Jun conform to the general
consensus motif (Pro)-X-Ser/Thr-Pro [(P)-X-S/T-P], as origi-
nally defined by substrate phosphorylation studies using the
archetypical MAPKs, the ERKs (7, 60, 113). This consensus
sequence indicates the ability of MAPKs to phosphorylate
either Ser or Thr residues (S/T) within a Pro (P)-containing
sequence. JNKs, like other MAPKs, such as the ERKs and the
related CDKs, are therefore considered Pro-directed Ser/Thr
protein kinases. An explanation of the structural basis for the
requirement for a Pro residue immediately following the phos-
phorylated Ser/Thr has been offered by the structure of the
complex of CDK-2 with cyclin and a substrate peptide (34).
Specifically, the presence of any amino acid other than Pro in
this position would result in an uncompensated hydrogen bond
from the nitrogen of the substrate peptide backbone and would
therefore not be favored (34). A similar structural explanation
is also predicted for the MAPKs, including the JNKs.
The initial studies on JNK-mediated phosphorylation of c-
Jun also revealed a requirement for amino acid sequences,
known as the  domain or the JNK-binding domain (JBD),
distant from the amino acids to be phosphorylated (4, 66, 77,
152, 210). The JBD sequence within c-Jun is shown in Table 2,
and a general schematic diagram illustrating the relative posi-
tions of the phosphorylated residues in relation to the JBDs of
c-Jun and other substrates is shown in Fig. 4. These distant
targeting domains mediate interactions of other MAPKs with
their substrates, upstream activators, phosphatases, and scaf-
fold proteins (295) and thus are more generally termed com-
mon docking (CD) domains. The use of docking domains by
MAPKs can enhance the efficiency and specificity of substrate
phosphorylation (19, 99, 148, 276). Furthermore, small pep-
tides making up the JBD of c-Jun inhibit JNK activity (4).
FIG. 2. Structures of the JNKs. (A) Crystal structure of JNK3 (PDB accession no. 1JNK) (327). The structure is shown in ribbon representation,
colored from the N terminus to the C terminus with colors changing from blue through green and yellow to red. The ATP analogue adenylyl
imidodiphosphate is shown in stick representation in magenta. The same coloring scheme is used throughout the figure unless indicated otherwise,
and the structures are in approximately the same orientations. (B) Crystal structure of JNK1 (shown in surface representation) in complex with
the peptide corresponding to residues 153 to 163 of the substrate and scaffold protein JIP1 (magenta, in stick representation) and the ATP-
competitive inhibitor SP600125 (pink, in stick representation) (PDB accession no. 1UKI) (129). (C) Crystal structure of the complex of p38 MAPK
(in surface representation) with a peptide corresponding to residues 269 to 280 of the substrate protein MEF2A (magenta, in stick representation)
(PDB accession no. 1LEW) (50). The figure was prepared using PyMol (DeLano Scientific LLC).
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However, as we describe in this review, docking sequences for
JNK have not yet been identified for all substrates of JNKs.
This raises the possibility that either these substrates are rec-
ognized independently of a docking site region or their docking
domains do not conform to the sequences currently recognized
as forming a JBD. The docking domains have significant im-
plications for the substrate specificity of JNKs, as discussed in
later sections of this review.
As mentioned in the opening paragraph, current analyses sug-
gest that 518 protein kinases form the human kinome (205).
Furthermore, if one-third of intracellular proteins can be phos-
phorylated, once various protein splice forms are taken into ac-
count, this may amount to some 20,000 phosphoproteins (151). A
simple calculation would therefore suggest that each protein ki-
nase should, on average, have 40 substrates. This calculation
does not take into consideration the idea that some proteins will
be phosphorylated at multiple sites by different protein kinases or
that many different protein kinases may phosphorylate the same
site on one substrate. The MAPKs are likely to be consistent with
this calculation, with an initial proteomic study identifying 25
phosphoproteins following ERK activation (189). Although not
all of these phosphoproteins may be direct substrates of ERK, this
does confirm the complexity of signaling events downstream of
MAPKs such as the ERKs.
OTHER NUCLEAR SUBSTRATES OF JNK
Early studies on the ERK subfamily of MAPKs suggested
that these kinases must be located within the same subcellular
compartment as their substrates and demonstrated that these
kinases could translocate to compartments such as the nucleus
upon exposure of the cells to the appropriate stimulation (114,
187, 300). Similarly, the JNKs have been shown to translocate
to the nucleus following cell exposure to agents that lead to
activation of the JNKs, including UV irradiation, osmotic
shock, and ischemia (47, 158, 223).
Transcription Factors as JNK Substrates
Proteins that act as transcription factors are regulators of
gene expression in eukaryotic cells. Typical transcription factor
structure includes a transactivation domain together with a
DNA-binding domain that recognizes specific DNA elements
within the promoters of target genes. Transcription factor ac-
FIG. 3. Summary of the substrates of JNKs discussed in this review. Following its activation by phosphorylation of a specific threonine and
tyrosine within its activation loop, JNK can phosphorylate a range of substrates. Phosphorylation can modulate the substrate protein activity in a
positive or negative fashion; JNK binding can even modulate the activity in a phosphorylation-independent manner. In some cases, the
consequences of phosphorylation by JNK have not yet been defined. The mitochondrial protein Bcl2 is shown as a protein that is both activated
and inhibited following its phosphorylation by JNK because currently there is evidence to support either effect (76, 146, 331). Similarly, JNK actions
on Bad have been shown to both increase and decrease its activity. In this example, these divergent effects have been attributed to the ability of
JNK to phosphorylate distinct sites (84, 344), although the effects of JNK-mediated phosphorylation of Bad Ser128 to increase its proapoptotic
actions have been questioned (347).
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tivity can be regulated, either positively or negatively, by a
number of biochemical processes, including phosphorylation
(Fig. 5A).
The Jun family of transcription factors. Phosphorylation
increases the transcriptional activity of c-Jun, as described in
the preceding section, as well as that of the related protein
JunD (Fig. 3) (339). JunD, although dispensable for develop-
ment, has been shown to be involved in muscle differentiation
(11) and has been implicated in the development of cardiac
hypertrophy (263). The JunD phosphorylation and docking
site sequences (Tables 1 and 2) are conserved in a shorter
splice form of JunD, -JunD, which lacks the N-terminal
menin interaction domain, suggesting that both JunD splice
forms are under the control of JNK phosphorylation (339).
The C-terminal part of JunD is also involved in interactions
with ERKs, thus allowing JunD regulation by both the ERK
and JNK pathways, and indeed, the N-terminal sites in JunD
are phosphorylated by both ERK and JNK (306, 309). The
sequences surrounding JunD Ser90 and Ser100 are analo-
gous to sequences surrounding Ser63 and Ser73 of c-Jun
(Table 1). Additionally, the sequence surrounding JunD
Thr117 shows similarity to the sequences surrounding c-Jun
Thr91, which is also phosphorylated by JNK (230). Note that
JNK binding to the JunD JBD has been shown to be poor
compared with JNK binding to the JBD of c-Jun or JunB
(117, 152). This is reinforced by the finding that c-Jun is a
more efficient substrate than JunD in vitro for four different
JNK isoforms (the jnk1 splice form JNK11, the jnk2 splice
forms JNK22 and JNK22, and the the jnk3 splice form
JNK31) (339). This study suggests that protein kinases
from the JNK family exhibit considerable specificities in
substrate docking and phosphorylation, even for related
transcription factor substrates.
Although the related transcription factor JunB was initially
not considered a JNK substrate because it lacks serine residues
in the appropriate consensus sequences (Ser74 and Ser84 in
murine JunB [accession number NP_032442], within the se-
quence G71QGS
74DTGASLKLAS84TELERL90) (152), subse-
quent studies showed that JunB is phosphorylated by JNK at
two closely spaced threonine residues, Thr102 and Thr104
TABLE 2. Summary of identified JBDsa
Protein (function) Experimentally determined JNK-binding sequenceb Reference(s)
Nuclear proteins
c-Jun (transcription factor) I33-L-K-Q-S-M-T-L-N-L-A43 77
JunB (transcription factor) K33-L-L-K-P-T-L-A-L-N-L-A44 339
JunD (transcription factor) L50-K-K-D-A-L-T-L-S-L-A60 339
ATF2 (transcription factor) K46-H-K-H-E-M-T-L-K-F-G56 118, 197
JDP2 (transcription factor) G153-N-L-L-E-Q-L-D-K-K163
c 155, 156
Elk-1 (transcription factor) G311-K-G-R-K-P-D-L-E-L-P321
d 321, 337
Net (transcription factor) S221-A-K-I-S-S-L-M-L-P-N-A-A233 86
HSF1 (transcription factor) G204-V-K-R-K-I-P-L-M-L-N-D215 65
c-Myc (transcription factor) C171-S-T-S-S-L-Y-L-Q-D-L-S-A-A-A-S-E187
e 6, 246
P53 (transcription factor) V97-P-S-Q-K-T-Y-H-G-S-Y-G-F-R-L-G-F-L-H-S-G117
f 41, 95
NFATc3 (transcription factor) P136-E-R-E-F-L-E-R-P-S-R-D-H-L-Y-L-P-L-E-P-S-Y-R-E-S-S-L162 57
NFATc1 (transcription factor) L126-G-L-Y-H-N-N-N-Q-F-F-H-D138 56
Glucocorticoid receptor (nuclear
hormone receptor)
A574-W-R-I-M-T-L-N-M-L 584
g 37, 266
Regulator of protein turnover
Itch (E3 ligase) R595-R-R-L-W-V-I-F-P-G604
h 100
Adaptor proteins
IRS-1 R849-L-A-R-P-T-R-L-S-L-G859 5, 185, 318
JIP1 R154-P-K-R-P-T-T-L-N-L-F164 245, 281
JIP2 H134-K-H-R-P-T-T-L-R-L-T144 338
JIP3 R202-K-E-R-P-T-S-L-N-V-F212 161
-Arrestin 2 L192-M-S-D-R-R-S-L-H-L-E202 218
Mitochondrial protein
Sab (function unknown) A310-V-V-R-P-G-S-L-D-L-R320 322
Regulator of cell movement
DCX DC domainsi 105
a A range of JNK substrate proteins also interact with JNKs via sequences remote from their phosphorylation sites. This table summarizes these proteins and provides
sequence information on the JBDs identified.
b The consensus sequence for JBDs has generally been shown to follow the pattern R/K2-3 -X1-6-L/I-X-L/I. Residues matching the consensus are shown in bold.
c Although JDP2 has a JBD-like sequence, this C-terminal sequence mediates the interaction with JNK.
d A Leu3233Ala/Ser3243Ala Elk-1 mutant failed to interact with JNK2 and was compromised in its interaction with JNK1, and thus the Elk-1 interaction site might
extend beyond this JBD.
e Not determined directly, but 171C-S-T-S-S-L-Y-L-Q-D-L-S-A-A-A-S-E187 is considered a  domain-like sequence (6, 246).
f A peptide sequence corresponding to p53 Val97 to Gly117 prevented complex formation between JNK and p53 (41, 95).
g Bruna and colleagues (37) identified this sequence as a potential mediator of the interaction of the glucocorticoid receptor with JNK in the context of the receptor
acting as an inhibitor of JNK.
h In the database sequence (accession no. CAI17960), this sequence corresponds to residues 533 to 542.
i The DC domains correspond to DCX residues 51 to 135 and 178 to 259.
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(Table 1) (1). Like in the case of c-Jun, these phosphorylation
sites are C-terminal to a conserved JBD sequence (Table 2 and
Fig. 4). Furthermore, this phosphorylation of JunB would ap-
pear to potentiate the transcriptional activity of JunB (Fig. 3),
as seen when a Thr1023Glu/Thr1043Glu mutant (designed
to mimic the JNK-mediated phosphorylation events) showed
enhanced ability to synergize with c-Maf in transcriptional
activation of the interleukin-4 promoter (1). Thus, this has
implicated the JunB protein in T-cell development and in
directing Th2 differentiation.
The ATF family of transcription factors. Together with the
transcription factors of the Jun family, the Fos and ATF2
families of bZIP transcription factors also form part of the
transcription factor complexes known as the activator protein 1
(AP-1) family (188). Within this transcription factor family,
there are additional substrates for JNK. While most evidence
supports the presence of a Fos kinase that is not related to JNK
(75, 288), ATF2 is recognized as a JNK substrate (118, 197). As
seen for JNK-mediated phosphorylation of c-Jun, JNK-medi-
ated phosphorylation of ATF2 is directed to two closely spaced
residues, namely, Thr69 and Thr71, in its N-terminal transac-
tivation domain (118, 197) (Tables 1 and 2). In a manner that
therefore shows similarity to c-Jun regulation by JNK, the
JNK-mediated phosphorylation of ATF2 enhances its tran-
scriptional activity (Fig. 3) (118, 197, 304).
Knowledge of the regions of ATF2 interacting with and
phosphorylated by JNK has led to the development of an
ATF2-derived protein fragment (ATF250–100). This peptide,
when delivered to cells, alters the balance between c-Jun and
ATF2 transcriptional activities, leading to the attenuation of
ATF2 activity and the induction of c-Jun activity as well as the
sensitization of cultured melanoma cells to chemotherapeutic
agents (26). These observations, together with recent studies
on the substrate-binding characteristics of ERK2 (226), sug-
gest that appropriate substrate-derived peptides will allow a
FIG. 4. Schematic diagram illustrating the relative positions of the phosphorylated residues in relation to the JBDs of c-Jun and 16 other
substrate proteins. At the bottom of the figure, the scale indicates the number of amino acids. Each protein substrate is represented by a solid line,
and the total number of amino acids in each protein is indicated on the right. The positions of the amino acids phosphorylated by JNK indicated
by the vertical lines are labeled with the residue phosphorylated (i.e., Ser or Thr [S or T] and its number in the sequence). The JNK-binding
domains are each denoted by a small box, and the residue numbers are indicated. The distances between the JNK-binding domains and the closest
residue phosphorylated are indicated, where positive numbers indicate that the phosphorylation sites lie to the C-terminal side of the JNK-binding
domain and negative numbers indicate that the phosphorylation sites lie to the N-terminal side of the JNK-binding domain. This information was
derived from the data presented in Tables 1, 2, and 3.
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subset of protein kinase substrates to be selectively inhibited.
This is a significant advance over the ATP-competitive inhib-
itors of kinases currently in use. ATP-competitive inhibitors
would be expected to inhibit the phosphorylation of all protein
substrates for a particular protein kinase and may not be spe-
cific for a particular kinase due to the difficulty in discriminat-
ing between the conserved ATP-binding sites of various pro-
tein kinases (for a review, see reference 92). Thus, a greater
understanding of the range of the possible intracellular JNK
substrates is critical in the development of new approaches to
achieve substrate-selective and specific inhibition of JNK.
There may be additional complex relationships between
JNK and the ATF family of transcription factors. While one
study has shown the importance of phosphorylation of residues
Thr51 and Thr53 in the N-terminal activation of ATFa for the
transcriptional activation of this specific transcription factor, it
appeared that ATFa was not a direct substrate for JNK2 (74).
Instead, the N-terminal domain of ATFa served as a docking
site for JNK (29), allowing ATFa-associated partners, such as
JunD, to then be phosphorylated by JNK (74). This relation-
ship emphasizes the possibilities of trans-phosphorylation
events in the regulation of transcription factor complexes.
JDP2 as a JNK substrate. JNK can also phosphorylate an-
other binding partner of c-Jun, i.e., Jun dimerization protein 2
(JDP2). JDP2 is a basic leucine zipper transcription factor
family member that interacts with c-Jun as well as the tran-
scription factors ATF2 and CCAAT/enhancer-binding protein
gamma (156). The site of phosphorylation of JDP2 has been
mapped to Thr148 (156) and a JBD identified in subsequent
studies (155) (Tables 1 and 2). It is important that although the
JDP2 sequence apparently contains a classic JBD consensus
sequence within its leucine zipper domain (i.e., K136NEKQH
LIYMLNLH149 [residues of the consensus are shown in bold]),
the site of interaction was mapped to the JDP2 C-terminal
region beyond residue 153 (155). Indeed, a 14-amino-acid frag-
ment derived from the JDP2 sequence (i.e., JDP2150–163),
when added to the transcription factor ATF3, which is usu-
ally not a JNK substrate, facilitated JNK phosphorylation of
ATF3; this sequence alone was therefore sufficient for JNK
interaction (155). In contrast to c-Jun-binding partners such
as c-Fos or ATF2, JDP2 acts as a repressor at the AP-1 site,
and it also inhibits Ras-driven transformation of NIH
3T3 cells and suppresses tumor formation in vivo in a PC3
cell xenograft model (128). The functional consequences
of JDP2 phosphorylation by JNK remain to be elucidated
(Fig. 4).
Elk-1 as a JNK substrate. JNK also phosphorylates a num-
ber of other transcription factors that do not form part of the
AP-1 complex. JNK phosphorylates the Ets domain-containing
transcription factor Elk-1 on Ser383 and Ser389 in its C-ter-
minal transactivation domain (Table 1); these same residues
are also phosphorylated by the ERK MAPKs (47, 132, 206,
321). This phosphorylation of Elk-1 increases its complex for-
mation with the serum response factor and, in this way, in-
creases transcriptional activity (Fig. 3) (107, 108, 321). The
binding of all 10 JNK isoforms (i.e., four JNK1 splice forms,
four JNK2 splice forms, and two JNK3 splice forms) to Elk-1
appeared considerably weaker than the binding of these JNK
proteins to either c-Jun or ATF2 (117, 337) (see Table 2 for the
Elk-1 JBD sequence). Although the exact residues within the
JBD required for binding either JNKs or ERKs do differ, p38
MAPK phosphorylation of Elk-1 does not appear to require an
intact JBD (337). These differences in specificity determinants
can thus play a pivotal role in producing unique nuclear re-
sponses following activation of the different MAPK pathways.
The requirement for specific docking domains and subse-
quent kinase-specific phosphorylation events is further illus-
trated by the observation that JNK binds to the ternary com-
plex factor Net (also known as Elk-3) via a binding motif
(Table 2) that is distinct from that bound by ERK or p38 (86).
FIG. 5. Major classes of known nuclear substrates of JNK. (A) A range of transcription factors have been shown to be JNK substrates.
JNK-mediated phosphorylation may be directed towards the transactivation domains, DNA binding domains, or other protein domains, and this
alters transcription factor activity. (B) A range of nuclear hormone receptors have also been shown to be JNK substrates.
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This JNK-mediated phosphorylation regulates nuclear export
of Net and inhibits Net-mediated effects (Fig. 3). The mecha-
nism of transcription factor inhibition can be explained by the
actions of JNK to phosphorylate four Ser residues of Net,
namely, Ser239, Ser245, Ser249, and Ser252 (Table 1), within
the Net nuclear export box, enhancing nuclear export. The
docking domain also shows homology to other JBD sequences
(Table 2). Interestingly, the Net residues phosphorylated by
JNK are distinct from those phosphorylated by ERK or p38,
and the actions are distinct from those of JNK-mediated effects
to increase the transcriptional activity of the related Ets family
transcription factor Elk-1 (Fig. 3). Heat shock factor 1 (HSF-1)
is another transcription factor that is also inactivated following
its phosphorylation by JNK (65). In this case, transcriptional
activity is decreased, rather than inhibition of its actions, re-
quiring its changes in nuclear localization. The site of phos-
phorylation in HSF-1 appears to be Ser363 (Table 1), one of
five Ser/Thr residues within S/T-P motifs. This phosphorylation
also depended on an interaction motif showing similarity to the
JBD of c-Jun (Table 2) (65). This inhibition by JNK-mediated
phosphorylation provides a mechanism, in addition to ERK-
mediated phosphorylation or interaction with a range of heat
shock proteins, to downregulate the actions of this transcrip-
tion factor (65).
c-Myc as a JNK substrate. Other transcription factors have
also been investigated as mediators of the nuclear actions of
JNK. In c-Myc, Ser61 and Ser71 have been shown to be phos-
phorylated by JNK1 and, to a lesser extent, by JNK2 and JNK3
(246). This phosphorylation increases c-Myc-mediated apop-
tosis (Fig. 3) (246). Interestingly, the related transcription fac-
tors s-Myc and Max are not JNK substrates (246). The region
of c-myc involved in the interaction with JNK was mapped to
residues 1 to 262 of c-Myc (246). This was subsequently con-
firmed in an independent study that blocked the binding of
JNK to c-Myc through the use of a peptide corresponding to
residues 127 to 189 of c-Myc (6). A  domain-like region of
c-Myc was identified within residues 171 to 187 (6) (Table 2).
p53 as a JNK substrate. The p53 tumor suppressor protein
is another transcription factor that is phosphorylated by many
protein kinases, including JNK (3). The interaction between
JNK and p53 has been mapped to amino acids 97 to 117 of p53
(Table 2) by the demonstration that a synthetic peptide corre-
sponding to these p53 residues prevented phosphorylation of
p53 and its interaction with JNK (3, 94). The overexpression of
the JNK pathway upstream kinase MEKK1 (Fig. 1) has been
shown to increase p53 stability and transcriptional activity (95),
and the p53 residue phosphorylated by JNK was subsequently
mapped to Thr81 (41) (Table 1). Phosphorylation of this res-
idue appeared to be critical for p53 stabilization and conferred
its transcriptional activity and ability to elicit apoptosis; in the
absence of JNK expression or JNK-mediated phosphorylation,
p53 was inactive (41). Thus, JNK can be considered an activa-
tor of p53 actions (Fig. 3). Interestingly, a JBD-like sequence
(I80-F-K-E-Q-G-L-T-L-P-L-Y91, with clear similarity to the
I33-L-K-Q-S-M-T-L-N-L-A43 sequence in c-Jun) has also been
described for the tumor suppressor protein BRCA2 (221).
However, the BRCA2 protein has not been shown to interact
with JNK (209), and other protein kinases have been suggested
to phosphorylate BRCA2 (220). This emphasizes that all po-
tential JBD-like sequences require experimental validation be-
fore any link with JNK-dependent signaling can be suggested.
Additional controversy surrounds the role of JNK-mediated
phosphorylation of p53, as the sites of phosphorylation are
only present in the rat sequence and not conserved in either
mouse or human sequences. This raises questions on the im-
portance of these phosphorylation sites in p53 function.
The NFAT family of transcription factors. Based on the
concept that distinct docking domains mediate JNK binding to
its substrates, JNK1 has been used as bait in a yeast two-hybrid
screen of a mouse embryo cDNA library in a search for novel
interacting partners and substrates (57). This screen revealed
an interaction of JNK1 with the transcription factor nuclear
factor of activated T cells c3	 (NFATc3; also known as NFAT4
or NFATx); the interaction was also confirmed in mammalian
cells (57). NFATs are calcium-sensitive transcription factors
that have been shown to be critical regulators of T-cell devel-
opment, and in addition to regulating other differentiation
programs, they function in a range of tissues, being involved in
skeletal muscle differentiation, cardiac valve development, and
osteoclast differentiation (135, 201). The functional utility of
the NFATs has been explained by their complex mechanisms
of regulation and their ability to integrate calcium signaling
with other signaling pathways (for a review, see reference 201).
The residues mediating interaction with JNK were mapped to
NFATc3 residues 162 to 207, with Ser163 and Ser165 as the
sites of phosphorylation (57) (Table 1; Fig. 4). In contrast to
the positive effects of JNK in enhancing transcription, as seen
in many of the preceding examples of transcription factor sub-
strates of JNK, this JNK-mediated phosphorylation of
NFATc3 again resulted in the nuclear exclusion of this tran-
scription factor (57). Thus, the activation of the JNK pathway
also antagonizes the actions of NFATc3 (Fig. 3).
JNK also phosphorylates the related NFAT family member
NFATc1 on Ser117 and Ser172, and this requires the pres-
ence of a JBD within residues 126 to 138 (56) (Tables 1 and 2
and Fig. 4). A comparison of the phosphorylation site se-
quences suggests that NFATc1 Ser172 is equivalent to
NFATc3 Ser165 (Tables 1 and 2). Both NFATc1 phosphory-
lation sites are close to the domain that interacts with the
calcium-dependent phosphatase calcineurin (56). Calcineurin
can preferentially dephosphorylate Ser172 in vitro, while the
phosphorylation of Ser117 was shown to be critical in regulat-
ing the targeting of calcineurin to NFATc1 (56). Thus, phos-
phorylation of NFATc1 by JNK inhibits the interaction with
calcineurin, thus blocking its nuclear entry and providing a
molecular mechanism for the observed increased nuclear lo-
calization of NFATc1 in the T cells of jnk1
/
 mice (83). This
antagonism of NFAT signaling by JNK activation is also seen
in other systems, such as the heart, where JNK activation
negatively regulates NFATc3 activation and inhibition of JNK
enhances NFAT signaling, with subsequent enhanced hyper-
trophic growth (192). These examples again illustrate the im-
portance of JNK in mediating the inhibition of transcriptional
events, in addition to its more widely acknowledged role as a
positive mediator of signaling.
In contrast to this negative regulation of NFAT signaling,
the phosphorylation of a different NFAT transcription family
member, NFATc2, by JNK stimulates its transcriptional activ-
ity (248) (Fig. 3). The effects of JNK required Thr116 (Table 1)
within the docking site for calcineurin in the NFATc2 regula-
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tory domain. No effect of JNK activation on the subcellular
localization of NFATc2 was observed (248). Importantly, these
different effects of JNK on the different NFAT isoforms high-
light the danger of studying the effects of JNK on one member
of a transcription factor family and then extrapolating these
effects to other closely related members of the same family.
Instead, functional testing appears to be required in each case.
The forkhead family of transcription factors. The forkhead
family member FOXO4 has also been shown to be phosphor-
ylated following the exposure of cells to TNF- or oxidative
stress in the form of hydrogen peroxide (90). The phosphory-
lation of the FOXO family has come under increasing atten-
tion as an event downstream of activation of the prosurvival
protein kinase Akt (for a review, see reference 39). For exam-
ple, the Akt-mediated phosphorylation of FOXO3a decreases
its transcriptional activity because phosphorylated FOXO3a is
bound by cytosolic 14-3-3 proteins and thus sequestered in the
cytosol. This prevents upregulation of the transcription of en-
zymes such as catalase and Mn-dependent superoxide dis-
mutase and thus changes the cellular levels of reactive oxygen
species (for a review, see reference 40). In contrast, a role for
JNKs was suggested more recently, based on the observation
that FOXO4 was no longer phosphorylated in cells deficient in
both JNK1 and JNK2 (i.e., jnk1
/
 jnk2
/
 cells) following
their exposure to hydrogen peroxide (90). JNK-dependent
phosphorylation enhanced FOXO4 transcriptional activity
rather than changing its binding to the cytosolic 14-3-3 proteins
(90) (Fig. 3). These results reveal a point of cross talk between
JNK and other signal transduction pathways. Further points of
cross talk will be discussed later in this review.
The positive regulation of FOXO activity in mammalian
cells (90) is consistent with studies of the model organism
Caenorhabditis elegans (247). In this organism, JNK interacts
with and phosphorylates the FOXO homologue DAF-16. Al-
though the phosphorylation sites appeared to be within the
N-terminal region of DAF-16 (residues 83 to 307), the residues
required for the interaction and for phosphorylation have not
yet been identified (247). The significance of this phosphory-
lation lies in the consequences of DAF-16 regulation. Specif-
ically, the negative regulation of DAF-16, as might result from
enhanced signaling from the insulin-like growth factor recep-
tor, has been associated with a shortened life span (for a
review, see reference 145). Thus, JNK activation and subse-
quent DAF-16 phosphorylation and activation resulted in an
increased life span, presumably through the upregulation of
genes promoting resistance to stress (247).
Similar results with FOXO regulation have also been
shown in Drosophila melanogaster, with dfoxo required for
JNK-mediated life span extension (313). Thus, in this range
of different systems, the FOXO forkhead transcription fac-
tors provide a point of convergence in signaling by the
insulin-like growth factor and JNK signaling cascades. It will
therefore be important to determine which of the mamma-
lian FOXO family members (for a review, see reference 27)
are regulated by JNK-mediated phosphorylation. Recent
evidence suggests that the JNK pathway is involved in the
regulation of the nuclear translocation of FOXO1, with JNK
phosphorylation leading to changes in the localization of the
transcription factor PDX-1, impairing PDX-1 function, as
observed in pancreatic  cells in diabetes (157). However, it
is not yet possible to discount a role for JNK as a negative
regulator of more membrane-proximal signaling events,
such as the phosphorylation of the adaptor protein insulin
receptor substrate 1 (IRS-1), as discussed below, which
would alter FOXO1 subcellular distribution through the
negative impact on Akt signaling. Again, this emphasizes the
likely contributions of multiple signaling pathways with ex-
tensive opportunities for cross talk and control.
The STAT family of transcription factors. Other transcrip-
tion factors are subject to control by multiple phosphoryla-
tion events. One example is the signal transducer and acti-
vator of transcription (STAT) family, which has been
implicated downstream of signaling by both cytokine and
growth factor receptors and whose members have been con-
sidered critical growth regulators (for a review, see refer-
ence 44). The phosphorylation of Tyr705 of STAT3 is me-
diated by the JAK family of tyrosine kinases, whereas JNK
also phosphorylates STAT3 on Ser727 (Table 1) (349). Both
phosphorylation events are required for full transcriptional
activation of STAT3 (Fig. 3). Similarly, the activation of the
JNK pathway downstream of protein kinase C- can also
result in the phosphorylation and activation of another
STAT family member, STAT1 (Fig. 4). This activation re-
quires phosphorylation of Ser727 (352) (Table 1). The in-
volvement of both STAT1 and STAT3 as mediators in a
range of diseases, including cancer, inflammatory disease,
and ischemia/reperfusion injury (for reviews, see references
255, 284, and 302), warrants further evaluation of the con-
tributions of JNKs to their initiation and development, as
JNKs may therefore play critical regulatory roles.
The Pax family of transcription factors. In addition to the
ability to modulate responses to stress through the phosphor-
ylation of a range of transcription factors involved in various
aspects of cell growth, as described above, JNKs may also
phosphorylate additional transcription factors involved in de-
velopment. The Pax family of transcription factors is required
for the embryonic development of a range of tissues (for a
review, see reference 55). Pax2 is required for kidney devel-
opment as well as for development of the inner ear and the
optic cup and has been shown to be a substrate for JNK. Pax2
can be isolated in a complex with the JNK-interacting protein
JIP1 (43). Phosphorylation enhances Pax2 transcriptional ac-
tivity (43) (Fig. 3). Although the phosphorylation site(s) in
Pax2 was not identified, it is possible to predict possible phos-
phorylation sites (Table 1) by using the consensus sequence
derived from other JNK substrates (329). It will now be inter-
esting to map the JNK phosphorylation sites in Pax2 and com-
pare these with the predicted sites. In addition, it will be critical
to identify possible JNK interaction motifs and to evaluate
whether other Pax family members might be regulated by the
actions of JNK.
TCF1 as a JNK substrate. Other transcription factors, such
as the POU domain-containing protein T-cell factor 1
(TCF1), a key regulator during development and lymphocyte
activation, also appear to be substrates for JNK, with TCF1
being phosphorylated at both the Ser232 and Thr242 residues
(Table 1) within its DNA-binding domain (154). This phos-
phorylation increases the binding of TCF1 to DNA and thus
likely mediates an increase in transcriptional actions following
JNK activation in T cells (154) (Fig. 3). Therefore, in many of
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the examples discussed thus far, phosphorylation by JNK in-
creases the activities of a range of transcription factor proteins
(Fig. 3).
Nuclear Hormone Receptors as JNK Substrates
Nuclear hormone receptors form a specific subset of tran-
scription factor proteins containing a DNA-binding domain
which are regulated through direct interaction with families of
hydrophobic hormones, such as steroids and the retinoids (Fig.
5B). In addition to the actions of JNK to modulate the activ-
ities, localization, or stabilities of the transcription factors de-
scribed in the preceding section, JNK has also been shown to
directly phosphorylate many nuclear hormone receptors. For
example, peroxisome proliferator-activated receptor 1
(PPAR-1) is a substrate for JNK (45). PPARs bind to re-
sponse elements in complex with the retinoic acid receptor and
activate transcription in response to a range of endogenous
ligands, such as fatty acids and arachidonic acid metabolites, or
foreign ligands, such as the antidiabetic drugs thiazolidinedio-
nes. JNK phosphorylates Ser82 (Table 1) in the transactivation
domain of PPAR-1, and this decreases its transcriptional ac-
tivity (Fig. 3) (45). This phosphorylation may contribute to the
development of insulin resistance when adipose tissue releases
TNF- and then signaling via the JNK pathway suppresses
PPAR-1 activity in vivo.
The glucocorticoid receptor has also been shown to be neg-
atively regulated through its phosphorylation by JNK (266)
(Fig. 3). The major site of phosphorylation of the rat glucocor-
ticoid receptor by JNK in vitro was mapped to Ser246 (Table
1). This site was confirmed within cultured cells (266) and was
one of four major phosphorylation sites within the N-terminal
transcriptional regulatory region (175). Thus, this JNK-medi-
ated inhibition would decrease the actions of glucocorticoids to
induce differentiation, regulate gluconeogenesis, and suppress
inflammation. Further studies using a form of the human glu-
cocorticoid receptor mutated to prevent phosphorylation by
JNK (i.e., Ser2263Ala mutant) suggested that JNK-mediated
phosphorylation of the glucocorticoid receptor enhanced nu-
clear export, apparently by a leptomycin B-sensitive, exportin/
CRM1-dependent mechanism (147). This provides an addi-
tional mechanism for inhibition of its effects in cells and is
similar to the enhancement of nuclear export of the transcrip-
tion factors Net and NFATc3 described above. The p38
MAPKs were also shown more recently to inhibit glucocorti-
coid receptor actions, in this case by indirectly targeting the
ligand-binding domain (289). This observation demonstrates
that there are multiple mechanisms of inhibition of the tran-
scriptional activity of this nuclear hormone receptor.
Conversely, glucocorticoids also inhibit the actions of the
JNK pathway (115). This has been attributed to the ability of
the glucocorticoid receptor to interact directly with JNK and to
inhibit its activity (37). An interaction motif showing similari-
ties to the motif in c-Jun was seen in the glucocorticoid recep-
tor (37) (Table 1). Furthermore, this JBD-like sequence was
shown to be required for glucocorticoid-induced nuclear local-
ization of JNK, suggesting a role for the glucocorticoid recep-
tor in shuttling JNK to the nucleus (37). Interestingly, the
nuclear translocation of JNK also increased JNK binding to
the AP-1-associated response elements in the c-jun gene, and
this binding of inactive JNK may maintain repression of AP-
1-dependent transcription (37). Clearly, these observations
show that all potential JBD-like sequences require experimen-
tal validation before any conclusions about their roles in the
regulation of JNK-dependent signaling can be drawn.
The retinoic acid receptors RXR and RAR have also been
shown to be substrates of JNK, providing one mechanism to
explain how stress can inhibit retinoid signaling (2, 181, 283).
Interestingly, RXR is a substrate for JNK as well as the dual-
specificity kinase MKK4/SEK1, the latter of which is usually
considered a JNK activator only (181). MKK4/SEK1-mediated
phosphorylation of RXR inhibited retinoid-mediated tran-
scriptional signaling, providing some of the first evidence that
MKK4/SEK1 can initiate effects independent of its actions on
JNK activation (181). The sites of phosphorylation for MKK4/
SEK1 were in domains distinct from those phosphorylated by
JNK (181). Although the residues phosphorylated by JNK
were not identified, mutation of a single tyrosine in RXR
(Tyr249) decreased phosphorylation and abrogated the ability
of MKK4/SEK1 to suppress transcriptional activity (181). This
is in contrast to the actions of JNKs as Ser/Thr kinases and
highlights the possibility that there may be many control points
for regulation of retinoid receptor activities.
Initial reports suggested that JNK mediated the phosphory-
lation of RXR at residues Ser61, Ser75, Thr87, and Ser265
(Table 1) (2). This phosphorylation did not appear to affect the
transactivation properties of either RXR homodimers or
RXR/RAR heterodimers (2). More recently, the phosphor-
ylation of the three N-terminal residues within the transacti-
vation domain has been shown to be required for the maximal
transcriptional activity that results from the cooperation of
RXR and its partner RAR (106). In addition, the impor-
tance of the phosphorylation of Ser265 was also highlighted
more recently; this residue lies outside the classic transactiva-
tion domain of RXR in the omega loop of the ligand-binding
domain (35). This phosphorylation enhanced the expression of
some retinoic acid target genes but decreased the expression of
others (35). Thus, JNK-mediated phosphorylation affects
RXR function by modulating its transcriptional effects (Fig.
3). This altered regulation of retinoic acid target genes may
thus have important consequences for retinoic acid actions in
the cell, as seen for the cooperation of retinoic acid and arsenic
trioxide in apoptosis through the JNK-mediated phosphoryla-
tion of RXR (298).
JNK has also been implicated in the inhibition of RXR
transactivation when cells are exposed to stress in the form of
arsenic trioxide (204). Mutational analysis has suggested the
requirement for Ser32, suggesting this as the novel Ser target
for JNK involved in the inhibition of nuclear receptor function
(Table 1) (204). The mechanism of this inhibition requires
further evaluation, as direct effects on stability, dimer forma-
tion, or interaction with DNA have not been observed (204).
The JNK-mediated phosphorylation of RAR was recently
mapped to residues Thr181, Ser445, and Ser461 (Table 1)
(283). This phosphorylation results in the inhibition of RAR
through induced proteasomal degradation of RAR (Fig. 3)
(283). Specifically, when a RAR mutant lacking these JNK
phosphorylation sites was expressed in cells, UV irradiation
did not lead to decreases in RAR levels. Conversely, inhibi-
tion of JNK in a human lung cancer cell line by the use of the
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JNK inhibitor SP600125 enhanced RAR levels. This link be-
tween the JNK signaling pathway and degradation of specific
proteins is explored further in the following section; for exam-
ple, the E3 ligase Itch has been shown to be a specific substrate
for JNK.
Other mechanisms, such as alterations in nuclear export,
remain to be investigated, particularly following the observa-
tion that the orphan nuclear receptor family member nur77 is
phosphorylated in its N terminus by JNK (174). This JNK-
mediated phosphorylation of nur77 is involved, in conjunction
with phosphorylation by Akt, in the modulation of nur77 func-
tions through regulation of nur77 nuclear export (Fig. 3) (121).
The exact residues in nur77 that are phosphorylated by JNK
remain to be identified (Table 1). JNK-mediated phosphor-
ylation of Ser650 of the androgen receptor (Table 1) was
also recently shown to increase its nuclear export to de-
crease its transcriptional activity (Fig. 3) (109). Thus, the
regulation of subcellular localization by JNK-mediated
phosphorylation can be a critical control mechanism in sig-
naling downstream of JNKs.
Additional Nuclear Proteins as JNK Substrates
In addition to the groups of transcription factors and nuclear
hormone receptors described as JNK substrates above, other
nuclear proteins are phosphorylated by JNK. For example,
heterogeneous nuclear ribonucleoprotein K (hnRNP-K) is
part of a large family of nuclear RNA-binding proteins and has
been implicated in diverse cellular and molecular functions,
such as nuclear-cytoplasmic shuttling and RNA transcription
and translation (for a review, see reference 31). hnRNP-K was
identified as a JNK substrate through a chemical genetic ap-
proach that used an ATP analogue and a JNK mutant specif-
ically modified in its ATP-binding pocket to use this ATP
analogue (119). Thus, two modifications were made to JNK2
(Met1083Gly and Leu1683Ala) to allow its use of the ATP
analogue N6-(2-phenythyl)-ATP. Following expression of this
JNK2 mutant in 293T cells and its activation following expo-
sure to UV irradiation, incubation of this kinase in the pres-
ence of protein extracts prepared from 293T cells and radio-
labeled N6-(2-phenythyl)-ATP allowed the visualization of
radiolabeled proteins separated by two-dimensional gel elec-
trophoresis. Tandem nanoflow electrospray mass spectrometry
of silver-stained spots that corresponded to phosphorylated
proteins identified three peptide sequences, with each corre-
sponding to a peptide from hnRNP-K (119).
Mutational analysis of the hnRNP-K protein has suggested
that JNK phosphorylates two sites, Ser216 and Ser353 (Table
1), although a JBD has not been identified (119). JNK phos-
phorylation of hnRNP-K did not affect inhibition of RNA
translation by hnRNP-K (120), but it was shown to enhance the
ability of hnRNP-K to drive AP-1-dependent reporter gene
expression (Fig. 3) (119). It will be critical to identify how the
JNK-mediated phosphorylation of hnRNP-K contributes to its
functions in cells, particularly when there are reports that
phosphorylation by other protein kinases, such as ERKs and
those of the Src family, can regulate hnRNP-K function in
translation (31). hnRNP-K has also been shown to function
within the DNA damage response pathway, being a target of
the HDM2 ubiquitin ligase that is thus stabilized in response to
DNA damage stimuli, such as UV irradiation (231). The sta-
bilized hnRNP-K protein can then act as a transcriptional
coactivator of the p53 protein (231). It will thus be of consid-
erable interest to evaluate whether phosphorylation controls
hnRNP-K activity to allow fine-tuning of DNA damage-in-
duced transcriptional events. Surprisingly, the study identifying
hnRNP-K as a JNK substrate appears to be the only study to
date to use a chemical genetic approach for the identification
of JNK substrates (119). This may reflect the limited availabil-
ity of the modified ATP analogue, although a recent report has
extended this approach with the use of ATP analogue inhibi-
tors and sensitive JNK mutants to dissect the time course of
signal transduction of JNKs in primary murine embryonic fi-
broblasts in response to TNF- (305).
Additional substrates may also help to explain other stress-
activated nuclear responses in cells. The exposure of cells to
stress decreases the expression of many gene families, includ-
ing the expression of genes encoding ribosomal proteins and
splicing factors (232). The mechanism has been investigated,
with inactivation shown to result from phosphorylation of the
polymerase I (Pol I)-specific transcription factor TIF-IA by
JNK at Thr200 (211) (Table 1). This phosphorylation abro-
gates complex formation between TIF-IA, Pol I, and the
TATA-binding protein-containing factor TIF-IB/SL1 (211)
(Fig. 6). The overexpression of the Thr2003Val mutant of
TIF-IA that cannot be phosphorylated by JNK was shown to
prevent inactivation of TIF-IA and thus lead to Pol I transcrip-
tion even in the presence of stress (211). Thus, JNK-dependent
phosphorylation of TIF-IA following the exposure of cells to
stress provides a mechanism to prevent ribosomal synthesis
(Fig. 3). This mechanism represents global control of protein
translation during stress and may thus act as a protective mech-
anism for the cell under these situations.
Taken together, the studies outlined in this and the preceding
section highlight the range of nuclear proteins that are JNK sub-
strates. However, active JNK is not restricted to the nucleus and
so may have an equally complex range of nonnuclear substrates.
For example, the arrestin proteins were recently shown to interact
FIG. 6. The nucleolus as a JNK-responsive stress sensor. (A) rRNA
synthesis under normal cellular conditions requires the actions of a pro-
tein complex including the Pol I-specific transcription factor TIF-IA, Pol
I, and the TATA-binding protein-containing factor TIF1B/SL1. (B) The
Pol I-specific transcription factor is phosphorylated by JNK, abrogating
complex formation and inhibiting ribosomal synthesis, when JNKs are
activated following the exposure of cells to stress.
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with JNK and allow for the relocalization of JNKs from the
nucleus to the cytoplasm (282). In the following sections, we
present an overview of nonnuclear JNK substrates that contribute
to diverse cellular responses, including protein degradation, signal
transduction, apoptotic cell death, and cell movement.
LINKS BETWEEN JNK ACTIVATION AND
PROTEIN DEGRADATION
The controlled degradation of proteins provides cells with a
robust approach to controlling protein activity. Proteins destined
for degradation are thus modified in a highly regulated fashion
through their covalent linkage to a conserved 76-amino-acid pep-
tide, ubiquitin (for a review, see reference 256). Indeed, the at-
tachment of multiple ubiquitin molecules, as mediated by a series
of ubiquitin-activating enzymes (E1), ubiquitin-conjugating en-
zymes (E2), and ubiquitin-protein ligases (E3), provides the basis
for defining proteins targeted for degradation by the 26S protea-
some (256) (Fig. 7). Although the processes of phosphorylation
and degradation have been considered separate intracellular
events, the possible links between the control of protein ubiquiti-
nation and protein phosphorylation are increasingly being recog-
nized (for a review, see reference 101).
Studies of T Cells Reveal that the E3 Ligase Itch
is a JNK Substrate
There has been a long-standing interest in the roles of JNK
in T-cell differentiation and function (82, 83, 265, 334). An
evaluation of T cells isolated from mice that express an inactive
form of the JNK pathway upstream activator (i.e., Mekk1
KD
mice) identified a role for JNK-dependent events associated
with protein degradation (102). In the T cells of these animals,
the increased levels of production of interleukin-2 and the
downstream cytokines interleukin-5, interleukin-10, and inter-
leukin-13 were accompanied by increased protein levels (but
not mRNA levels) of the transcription factors c-Jun and JunB
(102). The enhanced stability of these transcription factors was
confirmed in pulse-chase experiments, suggesting that the JNK
pathway may assist in accelerating protein turnover in CD4 T
cells and thus may have a role in their polarization into Th1
and Th2 effector cells.
The similarity between the phenotypes of these Mekk1
KD
T
cells and those isolated from animals with disruption of the E3
ligase Itch prompted an evaluation of the functions of JNK
(102). Specifically, the E3 ligase Itch was found to be a sub-
strate of JNK with multiple sites of phosphorylation, including
Ser199, Ser222, and Ser232 (Table 3). A specific JBD conform-
ing to the general features observed in the JBD of c-Jun was
also identified (Table 2) (100), but it should be noted that the
hydrophobic residues in the Itch JBD (i.e., Val600 and
Phe604) differ from those in many of the other JBDs, where
these residues are usually Leu (e.g., in c-Jun [Leu40 and
Leu42] or JIP-1 [Leu161 and Leu163]). It will therefore be
interesting to compare the exact modes of interaction of JNK
with this JBD.
The JNK-mediated phosphorylation of Itch enhances pro-
tein degradation (102) (Fig. 3), and this has been attributed to
phosphorylation-dependent conformational changes in Itch
(100). This mechanism differs from the E3 ligase Fbw7-con-
taining Skp/Cullin/F-box protein complex (SCFFbw7), which is
FIG. 7. Links between JNK and protein degradation. The degradation of proteins follows their covalent modification by polyubiquitination, a
multistep reaction requiring the actions of E1, E2, and E3 ligases. The JNK-mediated phosphorylation of the target protein or E3 ligases, such as
Itch, can alter the rates of protein degradation. For Itch, the activities are enhanced, but controversy remains on whether all actions of JNKs on
protein degradation will result in enhanced degradation.
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targeted to phosphorylated proteins, such as phosphorylated
c-Jun (240). The regulation of Itch activity by JNK phosphor-
ylation has the potential to allow the coordinated regulation of
degradation of many different cellular proteins and thus broad-
ens the actions of JNK phosphorylation. Within the context of
TNF--induced cell death, JNK activation of Itch allows for
the degradation of c-FLIP, an inhibitor of caspase-8, and thus
the subsequent cleavage of Bid to form tBid (52). Thus, pro-
longed JNK signaling is proapoptotic. Additional known Itch
targets include c-Jun (102) and JunB (91). It will be important
now to identify other processes modulated by phosphorylated
Itch and determine how these actions integrate with those of
the known targets.
JNK Targeting of Transcription Factors for Degradation
In contrast to the studies on Itch-mediated degradation and
its enhancement following JNK-mediated phosphorylation of
Itch, there remains some disagreement on the roles of JNK in
mediating degradation of transcription factor substrates. Spe-
cifically, biochemical studies have suggested that the binding of
inactive JNK to a number of its transcription factor substrates
targets these proteins for degradation. For example, associa-
tion of inactive JNK with c-Jun enhances c-Jun ubiquitination
(96). However, the phosphorylation of c-Jun Ser63 by active
JNK protected c-Jun from ubiquitination and increased its
half-life (96) rather than enhancing its degradation, as more
recently reported (240). JNK binding to promote degradation
has also been reported for ATF2 and JunB, whereas JNK-
mediated phosphorylation of ATF2 or p53 protected these
proteins from degradation (95, 97, 98). In the specific case of
c-Jun stability, the de-etiolated 1 protein has been shown to
regulate c-Jun levels via the assembly of a multisubunit ubiq-
uitin ligase containing CUL4 (319). The role for JNK in this
process remains to be explored fully, as the coexpression of
JNK or deletion of the c-Jun JBD did not protect c-Jun from
degradation (319).
In contrast, JNK did not associate with Elk-1 or target this
transcription factor for degradation (98). It remains to be
tested whether some of the differences noted in the effects of
JNK on protein stability might have arisen due to the different
JNK isoforms tested, particularly in light of the recent report
that JNK1 and JNK2 can oppositely regulate p53 levels in cells
(291). It is also interesting that a recent study showed that the
tyrosine kinase c-Abl was able to promote the proteolytic de-
struction of damaged DNA-binding proteins and that this was
an action independent of the kinase activity of c-Abl (54). It
therefore appears that despite the lack of consensus on the
effects of JNK-mediated phosphorylation on protein degrada-
tion, there may be multiple levels of control by JNK. It will be
interesting to see whether JNK regulates the stability of the
other non-transcription factor substrates described in the sub-
sequent sections of this review. Furthermore, it will be impor-
tant to explore whether JNK-mediated phosphorylation can
alter the activities of other enzymes involved in posttransla-
tional modifications of proteins, such as recently shown for the
Akt-mediated phosphorylation and suppression of methyl-
transferase activity of EZH2 (48).
JNK PHOSPHORYLATION OF SCAFFOLD AND
ADAPTOR PROTEINS
In addition to modulating signaling events within the nu-
cleus and altering signaling events through directed degrada-
tion of signaling proteins, Ser and Thr phosphorylation events
may regulate membrane-proximal signaling. An important fea-
ture of many signaling pathways is their use of additional
binding proteins that lack enzymatic activity (for a review, see
reference 310). Depending on their exact mode of action in a
signaling pathway and, in particular, how many different path-
way components they interact with and modulate the actions
of, these may be referred to as scaffold or adaptor proteins.
Scaffold and adaptor proteins are used not only in the MAPK
pathways but also in the regulation of signaling by integrins
and G protein-coupled receptors and in metabolic and stress
signaling (for reviews, see references 70, 71, 200, 202, 213, 229,
262, 264, 271, and 277). Increasingly, it is recognized that the
phosphorylation of these scaffold or adaptor proteins may alter
interactions with their binding partners and thus act as critical
new ways to modulate intracellular signaling events. Figures 8
and 9 summarize the actions of JNK on four different scaffold
molecules that are discussed in further detail in the following
sections.
IRS-1: a JNK Substrate That Allows Signal Integration
between Stress and Metabolic Events
In the signaling events following activation of the receptors
for insulin or insulin-like growth factor, the insulin receptor
docking protein known as IRS-1 is phosphorylated at multiple
tyrosine residues, and these residues then act to recruit SH2
domain-containing signal transducers, including phosphatidyl-
inositol 3-kinase, Grb2, Shp2, and Crk (for a review, see ref-
erence 320) (Fig. 8A). There are also many potential Ser phos-
phorylation sites within IRS-1, and many different Ser/Thr
protein kinases have been shown to phosphorylate IRS-1.
These kinases include mammalian target of rapamycin
(mTOR), protein kinase C-, and AMP-activated protein ki-
nase as well as JNK (5, 46, 133, 149, 196, 250). These different
kinases indicate that insulin signaling can be modulated by a
range of growth factors, cytokines, and stresses.
A major site of phosphorylation of IRS-1 by JNK has been
mapped to Ser307 (Table 3) and has been proposed to cause
insulin insensitivity following increased levels of inflammatory
cytokines, such as TNF- (5) (Table 3). Ser307 is adjacent to
the IRS-1 phosphotyrosine-binding domain (Fig. 8A), and its
phosphorylation interferes with the interaction of the insulin
receptor and IRS-1, thus preventing IRS-1 tyrosine phosphor-
ylation and decreasing insulin action (5). The actions of JNK
on IRS-1 require the ability of JNK to interact with IRS-1, and
the JNK-binding domain of IRS-1 has been mapped to 1 of 14
sites with L-X-L motifs typical of the JNK-binding domains (as
described in the preceding sections for substrates such as c-
Jun) (5, 185) (Table 2). Mutation of this JBD therefore not
only reduces Ser307 phosphorylation of IRS-1 but also in-
creases insulin-stimulated tyrosine phosphorylation and activa-
tion of downstream events, such as the activation of the protein
kinase Akt (185). The significance of this JNK-mediated event
was seen when these studies were extended to understand the
VOL. 70, 2006 JNK SUBSTRATE PROTEINS 1075
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
m
br.asm
.org/
D
ow
nloaded from
 
role of JNK signaling in mediating insulin sensitivity in vivo.
Specifically, the phosphorylation of Ser307 of IRS-1 was ob-
served in the livers of wild-type mice fed a high-fat diet (which
showed signs of insulin resistance) but not in the livers of
jnk1-deficient mice also fed this high-fat diet (which did not
develop insulin resistance) (134). (The numbering of IRS-1
here comes from the murine IRS-1 sequence [1,231 amino
acids in the full-length protein], which differs from the human
IRS-1 sequence [NP_005535; 1,244 amino acids in the full-
length protein]. Thus, serine 307 of the murine sequence cor-
responds to serine 312 of the human IRS-1 sequence and is
within the conserved sequence TATSPASM [the phosphory-
lated serine is underlined]. This should not be confused with
murine IRS-1 serine 302, which corresponds to human IRS-1
serine 307, within the conserved sequence RTESITAT. The
phosphorylation of human IRS-1 serine 307 has been reported
to be critical, and insulin signaling and its attenuation of phos-
phorylation have been linked to insulin resistance in patients
with type 2 diabetes [68].) These results are further supported
by studies using overexpression of dominant-negative JNK mu-
tants (238). These studies suggest a critical role for the JNK1-
mediated phosphorylation of IRS-1 in the development of
insulin resistance in diabetes. Thus, JNK inhibition is attracting
increasing attention as a strategy in the treatment and preven-
tion of insulin resistance in diabetes (for a review, see refer-
ence 136). There may be further benefits to also treating in-
sulin resistance in a diverse range of disorders, including
hypertension (285), skeletal muscle disuse atrophy (131), and
burn injury (348).
JNK has further been shown to phosphorylate IRS-1 at two
additional sites. Ser302 (Table 3) phosphorylation was demon-
strated to be important in mediating disruption of binding of
IRS-1 to the insulin receptor (318). In addition, Ser318 (Table
3), which was first identified as a novel protein kinase C--
dependent phosphorylation site, has more recently been shown
to be a target for both JNK and mTOR (235). Other protein
kinases, such as the IB kinase, may also phosphorylate IRS-1
Ser307 (103, 104, 237). It will be important to evaluate whether
FIG. 8. Scaffold and adaptor substrates of JNK. Scaffold and adaptor proteins are critical nonenzymatic proteins in signaling pathways that have
been proposed to increase the efficiency and specificity of signaling events. The phosphorylation of these proteins, as mediated by JNKs, can alter
their functions within signaling pathways. IRS-1 (A), JIP1 (B), and Shc (C) are examples of scaffold and adaptor proteins that are JNK substrates.
The sites of phosphorylation by JNK are indicated, together with other interaction domains in these proteins, notably the pleckstrin homology (PH)
domain that interacts with phosphatidylinositol 3,4,5-trisphosphate (PIP3), the phosphotyrosine binding (PTB) domains and SH2 domains that
interact with tyrosine-phosphorylated (pY) proteins, SH3 domains that interact with proline-rich sequences, and phosphorylated tyrosine residues
that themselves may interact with SH2 or PTB domains of other intracellular proteins. The size of each protein is not represented to scale in this
figure, but the number of amino acids in each protein is provided in parentheses.
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the phosphorylation of Ser302, Ser307, and Ser318 of IRS-1
can be mutually exclusive events or whether their combined
phosphorylation allows for additive or synergistic effects to
inhibit IRS-1. These multiple sites of phosphorylation may
allow for greater control over subsequent signaling events.
JNK-Mediated Phosphorylation of Other Adaptor and
Scaffold Proteins
In addition to the phosphorylation of IRS-1, as discussed in
the preceding section, JNK also phosphorylates other adaptor
and scaffold proteins. An interesting observation is the phos-
phorylation of the JNK scaffold protein JIP1 (245, 281) (Fig.
8B). The JIP1 sequence contains 11 S/T-P sites. Mutagenesis
has shown JNK-mediated phosphorylation of multiple sites in
JIP1 and that the phosphorylation of JIP1 at Thr103 (Table 3)
is necessary for activation of the JNK module, suggesting a
possible feedback mechanism for JNK activation which allows
operation of the JNK pathway in a switch-like manner (245).
JIP1 might also be phosphorylated by kinases other than JNK
and facilitate JNK activation; evidence presented from two-
dimensional peptide mapping showed JIP1 phosphorylation at
multiple sites (245). However, in overexpression studies, a
Thr1033Ala mutant form of JIP1 was not phosphorylated
upon overexpression of JNK2 and its activation following glu-
cose deprivation (281). The use of this phosphorylation-defec-
tive mutant form of JIP1 has implicated JNK-mediated phos-
phorylation in the dissociation of the protein kinase Akt1 from
a JIP1-containing complex following glucose deprivation, thus
allowing the activation of Akt1 under these conditions (280).
Thus, JNK-mediated phosphorylation of JIP1 provides a crit-
ical point in the regulation of prosurvival pathways.
The JBD of JIP1 has been mapped to an L-X-L motif typical
of JBDs of substrates such as c-Jun and IRS-1 (80, 338) (Table
2). An 11-amino-acid peptide based on this JIP1 JBD sequence
has been characterized as an inhibitor of JNK (16, 18, 80) and
has been cocrystallized with JNK1 (129). This structure (Fig.
2B) provides the first insight into how JNK binds its protein
substrates through the docking region, which is remote from its
active site. Specifically, this structure shows how two conserved
hydrophobic residues, together with a proline and an arginine
within the JIP-derived peptide, are involved in interactions
with JNK (Fig. 2B). The structure agrees with biochemical
assays of the ability of this peptide to interact with JNK and act
as a substrate-competitive inhibitor through distorting the
ATP-binding cleft and inducing relative movement of the two
lobes (16, 18, 80). Another available structure of MAPK in
complex with a substrate is that of p38 MAPK bound to the
peptide derived from the transcription factor MEF2 (Fig. 2C)
(50). Although both peptides bind at locations remote from the
active site of the kinase, there are sufficient differences be-
tween the p38- and JNK-peptide structures to explain the spec-
ificity of JIP-derived peptides for binding to JNK (129).
A study examining JIP1 phosphorylation identified 35 sites,
8 of which were Ser/Thr motifs and possible phosphorylation
sites for JNK or other MAPKs (67). Interestingly, these phos-
phorylation sites were present within protein kinase-binding
motifs of JIP1, and no modifications were noted in SH3 and
PTB domains, which are critical for interactions of JIP1 with
proteins such as kinesin and -amyloid protein (67). This sug-
gests that phosphorylation may further regulate JIP1 interac-
tions with selective groups of binding partners; further exper-
imental evaluation is warranted. Whether other JNK scaffolds,
such as plenty of SH2 domains (POSH) (296, 328) or -arres-
FIG. 9. JNK-mediated phosphorylation regulates the binding activity of 14-3-3 protein family members. (A) 14-3-3 proteins are a class of
adaptor proteins that generally bind their phosphoprotein targets via the consensus motif R-S-X-p(S/T)-X-P. This interaction allows 14-3-3
proteins to act as cytosolic anchors for their binding partners by masking intracellular targeting motifs, such as nuclear localization signals. (B) Any
mechanism that would disrupt 14-3-3 protein interactions could thus allow the movement of binding partners to other regions of the cell. Specific
examples include the JNK-mediated phosphorylation of 14-3-3 proteins leading to the release of the proapoptotic Bcl2 family members Bax and
Bad to allow their movement to the mitochondria and the release of the tyrosine kinase Abl, allowing its translocation to the nucleus. There are
likely many other binding partners for 14-3-3 proteins that are affected in this way.
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TABLE 3. Summary of nonnuclear substrates of JNKs and their phosphorylated sequencesa
Protein (function [GenBank accession no.]) Phosphorylation sitesequence(s) Reference(s)
Regulators of protein turnover
Itch (E3 ligase [CAI17960]) S-G-N-N-S199-P-S-L-S 100
P-P-P-P-T222-P-R-R-P
S-V-N-G-S232-P-S-A-T
Adaptor proteins
IRS-1 (NP_034700) S-R-T-E-S302-I-T-A-T 5, 185, 318
I-T-A-T-S307-P-A-S-M 235
G-K-P-G-S318-F-R-V-Rc
JIP1 (Q9R237) G-F-A-A-S15-P-P-A-Ad 245, 281
L-H-I-A-S29-P-P-N-F
A-T-G-D-T103-P-G-A-E
S-R-S-S-S197-P-L-K-T
T-G-E-Q-T205-P-P-H-E
E-I-Y-L-T284-P-V-Q-R
D-C-L-S-S341-P-E-R-A
A-S-V-S-S421-P-Y-E-S
JIP3 S-A-A-A-T266-P-S-T-T 161
T-K-S-N-T276-P-T-S-S
S-A-A-V-T287-P-L-N-E
p66ShcA (P29353) E-E-L-P-S36-P-S-A-S 179
14-3-3 (cytosolic phosphoprotein binding protein)
 (AAC14343) E-I-L-N-S186-P-E-K-Ae 301
ε (CAA79659) E-I-L-N-S187-P-D-R-Ae
 (BAA11751) E-I-L-N-S184-P-E-K-A
 (AAF36093) E-I-A-N-S186-P-E-E-A
Mitochondrial proteins
Bcl2 (antiapoptotic [AAA53662]) A-A-R-T-S70-P-L-R-P 76, 331
Bcl-xL (antiapoptotic [CAA80661]) S-E-M-E-T47-P-S-A-I 163
Q-L-H-I-T115-P-G-T-A
Mcl-1 (antiapoptotic [AAF64255]) D-A-I-M-S121-P-E-E-E 142
S-L-P-S-T163-P-P-P-A
Bad (proapoptotic [Q61337]) K-G-G-S-T201-P-S-Q 344
E-E-E-L-S128-P-F-Rf 84
BimEL(proapoptotic [ACC40029]) A-P-P-A-S
65-P-G-P-F 258
BimL(proapoptotic [ACC39594]) P-Q-D-R-S
44-P-A-P-M 186
K-S-T-Q-T56-P-S*-P-Pb
T-Q-T*-P-S58-P-P-C-Qb
Bmf (proapoptotic [Q96LC9]) Not determinedg 186
L-S-P-A-S77-P-S-Q-G
Bax (proapoptotic [D47538]) S-Y-F-G-T167-P-T-W-Q 166
Sab (BAA25922) L-D-L-P-S321-P-V-S-L 63
Protein kinases
p90RSK (P18652) T-P-K-D-S381-P-G-I-P 350
Akt (P31749) M-I-T-I-T450-P-P-D-Q 275
Regulators of cell movement
Paxillin (focal adhesion-associated protein [AAD00648]) P-G-A-L-S178-P-L-Y-G 138
Microtubule-associated protein 2 (AAB48098) Not determinedh 51
I-T-P-G-T1605-P-P-S-Y
Microtubule-associated protein 1B (P46821) Not determinedi 160
A-S-T-I-S1208-P-P-P-P
S-P-L-R-S1400-P-P-L-I
I-S-P-L-T1788-P-R-E-S
H-S-S-S-S1819-P-P-I-D
R-D-L-S-T1853-P-G-L-E
Tau (microtubule-associated protein [NP_005901]) P-P-A-K-T181-P-P-S-S 340
S-G-Y-S-S199-P-G-S*-Pb
G-S*-P-G-S202-P-G-T*-Pb
G-S*-P-G-T205-P-G-S-Rb
S-R-S-R-T212-P-S-L-P
P-S-L-P-T217-P-P-T-R
I-V-Y-K-S396-P-V-V-S
Continued on following page
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tin (214), are also substrates for JNK-mediated phosphoryla-
tion remains to be evaluated. -Arrestin 2 has a characterized
JBD (Table 2) which is critical for interaction with and activa-
tion of JNK3 (218). Interestingly, this motif is not conserved in
-arrestin 1 (218), thus showing distinct mechanisms of inter-
actions with these different arrestin family members. In addi-
tion, the JIP family members JIP2 and the more distantly
related JIP3 both have JBD sequences (Table 2) (161, 338),
with JIP3 being shown to be phosphorylated by JNK at three
residues (Thr266, Thr276, and Thr287) (Table 3; Fig. 4) (161).
In contrast to the reported effects of JNK-mediated phosphor-
ylation of JIP1 modulating signaling via this scaffolded com-
plex, the phosphorylation of JIP3 by JNK does not appear to
contribute to the regulated formation of JNK complexes with
JIP3 (Fig. 3) (161). The functional consequences of JNK-me-
diated phosphorylation of JIP3 therefore require further in-
vestigation.
The mammalian Shc proteins represent another important
family of adaptor proteins. The Shc proteins are involved in a
range of signaling events, including cell survival (for a review,
see reference 262) (Fig. 8C). ShcA has three isoforms, and the
largest isoform, p66ShcA, is phosphorylated at Ser and Thr
residues in response to a range of stimuli (153, 217, 333).
Phosphorylation of Ser36 of p66ShcA has been implicated in
promoting the cell death response to oxidative stress; an in-
hibitor of this phosphorylation could therefore provide a novel
means for the treatment of diseases associated with oxidative
stress. The use of recombinant protein kinases in vitro and of
chemical protein kinase inhibitors in cultured cells has impli-
cated the JNKs as major mediators of the phosphorylation of
Ser36 of p66ShcA (Table 3) (179). No interaction motif has
been reported.
There has also been an increasing interest in the ability of
JNKs to phosphorylate 14-3-3 proteins. This family of cytosolic
binding proteins has been implicated in many biological pro-
cesses, including the regulation of cell proliferation and death
(71). 14-3-3 proteins generally bind phosphoproteins via the
consensus motif R-S-X-p(S/T)-X-P (233). This interaction al-
lows 14-3-3 proteins to act as cytosolic anchors for their bind-
ing partners by masking intracellular targeting motifs, such as
nuclear localization signals (Fig. 9) (234, 303). Any mechanism
that would disrupt 14-3-3 protein interactions could thus allow
the movement of binding partners to other regions of the cell.
JNK can phosphorylate the 14-3-3 isoforms  and  at
Ser184 and Ser186, respectively (301) (shown in Table 3,
alongside predicted JNK phosphorylation sites in 14-3-3  and
14-3-3 ε). Interestingly, the 14-3-3 isoforms , , and  do not
share an equivalent motif (301), suggesting different modes of
regulation for different 14-3-3 family members. JNK-mediated
phosphorylation of 14-3-3  or  promotes its dissociation from
the proapoptotic Bcl2 family member Bax and its translocation
to a mitochondrion, resulting in cell death (301). Conversely,
the overexpression of a 14-3-3 mutant that can no longer be
phosphorylated by JNK (e.g., the 14-3-3  Ser1843Ala mu-
tant) can inhibit Bax translocation, inhibit cytochrome c
release, and prevent cell death (301). Similarly, JNK-medi-
ated phosphorylation of 14-3-3 proteins promoted the re-
lease of the proapoptotic Bcl2 family member Bad to an-
tagonize prosurvival signaling initiated by protein kinases
such as Akt (286). Interestingly, the site of phosphorylation
TABLE 3—Continued
Protein (function [GenBank accession no.]) Phosphorylation sitesequence(s) Reference(s)
S-G-D-T-S404-P-R-H-L
D-M-V-D-S422-P-Q-L-A
Amyloid  protein precursor (microtubule-associated
protein [AAA36829])
D-A-A-V-T668-P-E-E-R 274
SCG10 (stathmin-like protein [AAB36428]) L-K-P-P-S62-P-I-S-E 242
T-L-A-S-S73-P-K-K-K
DCX (microtubule-associated protein [NP_034155]) S-Q-L-S-T321-P-K-S-K 105
S-P-I-S-T331-P-T-S*-Pb
S-T*-P-T-S334-P-G-S-Lb
Kinesin heavy chain (microtubule-binding protein
[P56536])
Not determinedj 227
R-F-V-S-S175-P-E-E-V
Keratin 8 (intermediate filament protein) Q-S-L-L-S73-P-L-V-L 127
a Nonnuclear proteins that have been implicated in a broad range of cellular functions have been demonstrated to be substrates for JNK-mediated phosphorylation.
This table summarizes these proteins and provides sequence information on the phosphorylation sites identified. For each phosphorylation site, a nine-amino-acid
sequence surrounding the residue that is phosphorylated is provided. As shown, multiple sites of phosphorylation have been identified for some nonnuclear proteins.
b In these sequences, S* or T* represents Ser or Thr residues that have also been shown to be phosphorylated by JNKs, showing that JNKs may phosphorylate a
number of closely spaced residues. It remains to be determined whether there is any requirement for hierarchical phosphorylation of these substrates by JNKs.
c The numbering of the sites refers to the murine IRS-1 sequence. In the human sequence (GenBank accession no. NP_005535), these correspond to the sequences
S-R-T-E-S307-I-T-A-T, I-T-A-T-S312-P-A-S-M, and G-K-P-G-S323-F-R-V-R.
d The numbering of the sites refers to the human JIP1 sequence.
e Phosphorylation sequences in 14-3-3  and 14-3-3 ε are predicted by sequence similarity with 14-3-3  and 14-3-3  (301).
f JNK phosphorylation of Ser128 of Bad and the role of this in apoptosis have been questioned (347).
g In the protein sequence, there are nine S-P and five T-P motifs, and the residues phosphorylated were expected to be similar to those shown in the same study to
be phosphorylated in the related protein BimL (186). The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus (Scansite [329] score,
0.13827).
h In the protein sequence, there are 21 S-P and 23 T-P motifs. The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus (Scansite
[329] score, 0.13827).
i In the protein sequence, there are 53 S-P and 26 T-P motifs. The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus (Scansite
[329] score, 0.13827).
j In the protein sequence, there are 12 S-P and 11 T-P motifs. The motifs shown in italics are the best S-P or T-P matches with the heptapeptide consensus (Scansite
[329] score, 0.27655).
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is adjacent to the ligand-binding groove of 14-3-3 proteins
(286), suggesting that binding of other ligands of the 14-3-3
proteins may be modulated by JNK-mediated phosphoryla-
tion. Indeed, the use of 35S-labeled cellular proteins showed
the release of a subset of bound proteins following 14-3-3 
phosphorylation by JNK (286).
The release of other classes of 14-3-3 protein-binding part-
ners has also been demonstrated for the protein tyrosine ki-
nase c-Abl (342). The nucleocytoplasmic shuttling of c-Abl
involves three distinct nuclear localization sequences and a
nuclear export sequence (254). In response to stress, such as
DNA damage or oxidative stress, c-Abl translocates to the
nucleus and, importantly, JNK is activated (254). JNK-medi-
ated phosphorylation of the 14-3-3 proteins allows nuclear
translocation of c-Abl, presumably because the bound 14-3-3
proteins usually interfere with recognition of the nuclear lo-
calization sequences (342; for a review, see reference 341).
This important regulatory role for 14-3-3 proteins has been
tested specifically with the overexpression of 14-3-3  to atten-
uate c-Abl translocation in response to DNA damage as well as
with the downregulation of 14-3-3 proteins (using small inter-
fering RNAs) to increase nuclear c-Abl (342). The link to
phosphorylation by JNK at residue Ser184 was further
strengthened by the observation that the 14-3-3  Ser1843Ala
mutant protein was more protective than the wild-type 14-3-3
 protein in c-Abl-mediated apoptotic events following expo-
sure to either DNA damage or oxidative stress (342).
Studies of 14-3-3 proteins have revealed the power of JNK
phosphorylation as a regulatory strategy, particularly when
rapid cellular responses are required. Furthermore, the poten-
tial to release many different binding partners for their actions
in different compartments of the cell, as exemplified by the
actions of Bax and Bad being freed to move to the mitochon-
dria or the movement of c-Abl to the nucleus, allows a highly
coordinated and rapid response without the requirement for
transcriptional events that may take a significantly longer time.
JNK-MEDIATED PHOSPHORYLATION OF
MITOCHONDRIAL PROTEINS
Since the initial characterization of JNKs as stress-activated
protein kinases, there has been speculation on whether these
kinases may be modulators of cell death in response to stress,
either by facilitating cell death or by opposing it. Substrates in
addition to c-Jun have been proposed to be involved in JNK-
mediated apoptosis (64). Thus, in addition to the c-Jun-depen-
dent transcriptional events that could mediate cell survival or
cell death (for a review, see reference 9), the actions of JNK to
phosphorylate 14-3-3 proteins (see the preceding section) and
to facilitate proapoptotic pathways have received increasing
interest.
JNK and the activator SEK may colocalize with mitochon-
dria in cardiac myocytes (12), and levels of JNK2 increase in
both the nuclei and mitochondria of cells of the PC12 neuronal
cell line upon exposure to 6-hydroxydopamine (88). This has
led to the suggestion that proteins of the outer mitochondrial
membrane may act as JNK substrates. The direct effects of
JNK activity on mitochondria have been studied in a cell-free
assay, where the addition of purified JNK led to the release of
cytochrome c from isolated mitochondria (12). In contrast,
dominant-negative mutants of JNK2 prevented apoptotic
events, including the release of cytochrome c, and the down-
stream events, such as cleavage of caspase 3 and poly(ADP)-
ribose (88). These results suggest significant roles for JNKs as
mediators of apoptotic cell death and for mitochondrial pro-
teins as JNK targets. The regulation of Bcl2 family members is
illustrated in Fig. 10 and described in the following section.
JNK-Mediated Phosphorylation of the Bcl2 Family
The Bcl2 family of mitochondrial proteins has increasingly
been implicated as regulators of cell death (for reviews, see
references 62 and 116), so events that change their activities
provide mechanisms to alter the death and survival decisions of
the cell. The founding member of this protein family, the
antiapoptotic Bcl2 protein, has been shown to be phosphory-
lated following cell exposure to a variety of stimuli, and JNK
has been implicated as the protein kinase in these events (208).
The phosphorylation of Ser70 (Table 3) was suggested to in-
activate the antiapoptotic function of Bcl2 (331). However, this
contradicts earlier suggestions that phosphorylation of this
Bcl2 site would enhance its antiapoptotic functions (146) or
subsequent studies that showed that Bcl2 phosphorylation at
Ser70 was associated with increased cell survival (76). It re-
mains to be evaluated whether this reflects the differences in
cell types examined, the type or level of the stimulus, or dif-
ferences in function upon Bcl2 phosphorylation at sites in
addition to Ser70.
Other antiapoptotic Bcl2 family members have also been
shown to be substrates for JNK. Specifically, JNK-mediated
phosphorylation of Thr47 and Thr115 of Bcl-xL (Table 3) can
inactivate the antiapoptotic actions of this protein in response
to cellular stresses such as ionizing radiation (Fig. 3) (163).
Similarly, JNK-mediated phosphorylation of Ser121 and
Thr163 of Mcl-1 (Table 3) in response to cellular stresses such
as oxidative stress can inactivate the antiapoptotic actions of
this protein (Fig. 3) (142). In contrast, the proapoptotic Bcl2
family member Bad has been shown to be phosphorylated at
Thr201 (Table 3), but in this case, phosphorylation suppresses
apoptosis by again inactivating the usual actions of this protein
(Fig. 3) (344). The latter example explains the requirement for
JNK as a mediator of interleukin-3-dependent survival of he-
matopoietic cells (344). Conversely, JNK phosphorylation of
Ser128 of Bad (Table 3) promotes the proapoptotic effects of
Bad in primary granule neuron cells (Fig. 3) by antagonizing
the actions of growth factors (84). However, it was recently
questioned whether Ser128 of Bad is phosphorylated by JNK,
and therefore the role of JNK in apoptosis mediated by the
Bad protein is not clear (347).
In addition, the proapoptotic protein BimEL has been shown
to be a JNK substrate, with phosphorylation of Ser65 (Table 3)
potentiating its proapoptotic actions following growth factor
withdrawal (Fig. 3) (258). In a separate study, the Bim family
members BimL (a splice form of the Bim gene, whose splicing
also results in BimEL and BimS) and Bmf were evaluated as
JNK substrates (186). BimL was phosphorylated at Thr56 and
at least one of Ser44 and Ser58 (Table 3), and Bmf was ex-
pected to be phosphorylated at similar sites. The predicted
sites for JNK-mediated phosphorylation of Bmf are also shown
in Table 3. For both BimL and Bmf, this phosphorylation
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inhibits their binding to dynein chain proteins that normally
sequester these proteins and prevent their proapoptotic activ-
ity. Thus, this provides another mechanism to explain the pro-
apoptotic functions of JNK. The JNK- and p38-mediated phos-
phorylation of the proapoptotic protein Bax has been shown
most recently to lead to Bax activation and translocation to the
mitochondria (Fig. 3) (166). In this case, the use of specific
phosphorylation site mutants has suggested that Bax Thr167 is
the target of JNK-mediated phosphorylation (Table 3) (166).
The effects of JNK-mediated phosphorylation of Bcl2 family
members should also be considered within the context of JNK-
dependent changes in the expression levels of these proteins.
For example, increased expression of Bim following arsenite
exposure or growth factor withdrawal was shown to be JNK
dependent (258, 323). As mentioned previously, Bax translo-
cation to mitochondria can also be modulated by JNK-depen-
dent phosphorylation of 14-3-3 proteins (301). Therefore, JNK
acts at multiple levels in the control of mitochondrial Bcl2
family function, and further work is required to comprehen-
sively profile which Bcl2 family members are substrates for
JNKs and how phosphorylation affects their functions in apop-
totic death.
JNK-Mediated Phosphorylation of Sab
The use of JNK as bait in a yeast two-hybrid screen also
identified the SH3 domain-containing mitochondrial protein
Sab (also known as SH3BP) as an interacting partner and
substrate for JNK (322). Sab was originally identified as a
binding partner and negative regulator of Bruton’s tyrosine
kinase (330). Of two JBD-like sequences, only one was shown
to be essential for the interaction with JNK (Table 2). The
same motif appears to also mediate interaction with the related
MAPK family member SAPK3 (63). In addition, only one of
the four Ser residues within an S-P motif were shown to be
phosphorylated (Table 3), and this was also the predominant
site for phosphorylation by SAPK3 (63). The function of Sab
and the way in which it might be altered upon phosphorylation
by MAPKs, such as JNK and SAPK3, require further investi-
gation.
REGULATION OF OTHER PROTEIN KINASES
THROUGH JNK-MEDIATED PHOSPHORYLATION
Protein kinases, in addition to catalyzing phosphorylation
reactions, can also be subjected to control by phosphorylation,
in some cases in an autophosphorylation reaction but in other
instances in reactions catalyzed by other protein kinases. Such
actions of protein kinases to regulate the activities of other
kinases are evident in the sequential activation of protein ki-
nases in the MAPK cascade, as shown in Fig. 1A, but there
remains the possibility that JNKs phosphorylate additional
protein kinase substrates. Two examples are shown in Fig. 11
and described in the following sections.
Phosphorylation of MAPK-Activated Protein Kinases
A feature of MAPKs is their ability to phosphorylate a group
of substrates that are themselves protein kinases. These sub-
strates are therefore termed the MAPK-activated protein ki-
nases. These protein kinases include the p90 ribosomal S6
kinases (RSK1-4), the mitogen- and stress-activated kinases
FIG. 10. Mitochondrial substrates of JNK and the regulation of cell death. (A) A number of mitochondrial proteins within the Bcl2 family of
apoptosis regulators are direct substrates of JNK phosphorylation. The actions of JNK-mediated phosphorylation to alter the actions of Bcl2 itself
remain controversial, and whether the phosphorylation of Ser128 of Bad is JNK mediated has been questioned (?). (B) The link between
JNK-mediated phosphorylation of Bim and Bmf proteins and increased cell death has been attributed to the disruption of binding of Bim and Bmf
to anchoring proteins, including the dynein and myosin V motor complexes.
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(MSK1-2), the MAPK-interacting kinases (MNK1-2), and the
MAPK-activated protein kinases (MAPKAPK1-5; also now
known as MK1-5) (for a review, see reference 268). Interest-
ingly, however, little evidence supports the direct phosphory-
lation of these protein kinases by JNKs (for a review, see
reference 268), with the exception of a report demonstrating
p90RSK phosphorylation on Ser381 (also known as RSK2) (Ta-
ble 1) by both ERK and JNK pathways following exposure of
cells to UV irradiation (350). MK1 shows the unusual organi-
zation of two kinase domains separated by an 100-amino-
acid linker, with the N-terminal kinase domain phosphory-
lating substrates and being controlled by the C-terminal kinase
domain and the linker (for a review, see reference 268). Ser381
is within the linker region between the two kinase domains in
MK1, and its phosphorylation has been shown to create a
docking site for 3-phosphoinositide-dependent protein kinase
1 (PDK1) (93) (Fig. 11A). This then leads to coordinated
phosphorylation and activation of both PDK1 and MK1 (93).
Thus, phosphorylation of this site can be considered an impor-
tant rate-limiting step in MK1 activation (Fig. 3); the involve-
ment of JNK in this process is consistent with the activation of
MK1 following exposure to stresses such as UV irradiation.
JNK-Mediated Phosphorylation of the Prosurvival Protein
Kinase Akt
The protein kinase Akt has been reported to be a JNK sub-
strate (275). Phosphorylation of this protein provides another
example of cross talk between the JNK and Akt pathways (in
addition to Akt phosphorylation and inhibition of the upstream
activators of the JNK pathway [MLK3, ASK, and MKK4/SEK1]
[20, 164, 252] or the binding of Akt to the JNK scaffold JIP1
[thereby preventing recruitment of the JNK signaling complexes]
[165]). Note that JNK phosphorylates Thr450 of Akt1 (Table 1).
This is only one of six candidate JNK phosphorylation sites in
Akt. This phosphorylation then primes Akt for phosphorylation
and activation by PDK1 (Fig. 11B), thus controlling, in part, the
basal activity of Akt, the efficiency of Akt activation after isch-
emia, and cell survival after ischemia (275). This priming effect
shows some similarities to the recent observation that phosphor-
ylation of Ser473 of Akt is also a priming event for subsequent
phosphorylation of Akt by PDK1 (270). Both Ser473 and Thr450
are in the hydrophobic tail region of Akt, and thus phosphoryla-
tion of these and possibly other residues in this domain of Akt
may serve to enhance interactions between Akt and PDK1, thus
providing additional links between Akt and other signaling path-
ways. Further examples of positive regulation of the Akt pathway
by JNK remain to be reported, as others have also shown negative
regulation of Akt phosphorylation following JNK overexpression
(157) and enhancement of Akt phosphorylation by a loss of JNK
signaling (287).
REGULATION OF CELL MOVEMENT THROUGH
JNK-MEDIATED PHOSPHORYLATION
Cell movement is a complex biological process requiring
coordinated changes in the activities of numerous protein com-
plexes, including actin polymerization, adhesion dynamics,
changes in cell polarity, and trailing edge retraction (for a
review, see reference 308). Critical molecular structures such
as the focal adhesions are now seen not only as structural
complexes but also as highly sophisticated and regulated sig-
naling networks (for a review, see reference 267). Initial stud-
ies on the JNK pathway in Drosophila suggested a role for JNK
in cell migration, with the loss of JNK function resulting in
failure of dorsal closure in the developing embryo (278). Sim-
ilarly, in mammalian cells, an upstream kinase in the JNK
pathway, MAPK/ERK kinase kinase 1 (MEKK1), was subse-
quently shown to be essential for cell migration (324, 345).
While transcription factor control by JNKs might contribute to
FIG. 11. Protein kinases as substrates of JNK. (A) The p90RSK protein kinase consists of two distinct protein kinase domains and a linker
domain. Phosphorylation of the linker domain by JNK leads to coordinated phosphorylation and activation of p90RSK and PDK1, which act
upstream of the prosurvival kinase Akt. (B) Akt can also be phosphorylated by JNK, and this leads to enhanced binding by the Akt activator PDK1,
thus increasing prosurvival Akt actions.
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this regulation of cell movement (for a review, see reference
249), the observed rapid effects upon JNK inhibition suggested
other targets for JNK action (138). A number of focal adhe-
sion, microtubule-associated, and intermediate filament pro-
teins are JNK substrates, and these are summarized in Fig. 12
and described in the following sections.
JNK-Mediated Phosphorylation of the Focal Adhesion
Protein Paxillin
Paxillin has been proposed as a JNK substrate based on its
localization in focal adhesions, its function as an adaptor protein
involved in cell migration and organization of adhesion, and its
Ser phosphorylation following cell exposure to fibronectin or
growth factors. In vitro kinase assays showed JNK phosphoryla-
tion of paxillin at Ser178 (Table 3), and the relevance of this
phosphorylation in cells was confirmed with the use of a
Ser1783Ala mutant of paxillin that was not phosphorylated by
JNK1 in NBT-II cells (138). The expression of this paxillin mutant
also slowed cell migration, as measured in time-lapse single-cell
motility assays and monolayers of cells subjected to wound-heal-
ing assays (138), suggesting that phosphorylated paxillin enhances
cell movement (Fig. 3). Similar results were obtained in wound-
healing assays using a variety of cell types, including MDA-MB-
231 human breast cancer cells and Chinese hamster ovary K1 cells
(138), and JNK-mediated phosphorylation of paxillin was recently
shown to be necessary for platelet-derived growth factor-induced
chemotaxis of primary foreskin fibroblasts (8). Furthermore, JNK
has been shown to localize to the actin-dense membrane ruffles at
the cell leading edge following growth factor exposure, suggesting
a critical role for JNK in cell migration (8). Taken together, these
studies suggest that JNK-mediated phosphorylation of paxillin is
a key event in the regulation of migration of many cell types.
In contrast to studies with mammalian cells, studies of Dic-
tyostelium have suggested that JNK may not have any major
effect on cell sorting, slug migration, or morphogenesis (38).
This conclusion was based on the lack of effects of mutant
forms of paxillin that were proposed to disrupt a possible JNK
phosphorylation site (38). It should be noted that within the
Dictyostelium paxillin sequence, Ser192 had been proposed as
a conserved JNK phosphorylation site (38). However, the se-
quence surrounding this residue (Q-P-A-L-S192-K-A-T-L) var-
ies markedly from the sequence surrounding Ser178 in human
paxillin (Table 3). Most notably, it lacks a Pro residue imme-
diately C-terminal to the Ser, and thus the likelihood that this
is a JNK phosphorylation site is less likely, though not impos-
sible. The Dictyostelium paxillin sequence (CAA05356) does
contain a number of the more favored S/T-P motifs. Whether
these are sites for phosphorylation and regulation by JNK or
other MAPKs, such as the ERKs, which also modulate cell
morphogenesis through interactions with paxillin (144), re-
mains to be evaluated.
JNK Interaction with and Phosphorylation of Microtubule-
Associated and Intermediate Filament Proteins
In addition to its nuclear localization, as discussed earlier in
this review, JNK localizes in fibroblasts to punctate structures
FIG. 12. Links between JNK substrates and cell movement. JNK can phosphorylate proteins, such as paxillin, localized within focal adhesions
or associated with microtubules or intermediate filaments. These actions can result in changes in cell migration and changes in microtubule
stabilization.
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along microtubules (236). Since microtubules are able to affect
focal adhesion turnover and are also implicated in aspects of
cell migration, the interaction and phosphorylation of micro-
tubules or their associated proteins could be another mecha-
nism for the regulation of cell motility. Indeed, the phosphor-
ylation of microtubule-associated protein 2 appears to be
required for binding to microtubules in intact cells (36). JNKs
were shown to phosphorylate microtubule-associated protein
2, at least in vitro (177). Microtubule-associated proteins 2 and
1B have been considered in vivo JNK targets only more re-
cently (51, 160), although the exact sites targeted for phosphor-
ylation by JNK remain poorly defined (Table 3).
When the activity of purified JNK1 protein towards crude
extracts of mouse brain was evaluated, microtubule-associated
protein 2 was shown to be a prominent substrate for the kinase
(28). The use of neurons isolated and cultured from jnk1
/

mice showed an increased dendritic arbor number and de-
creased arbor length. For these cultured cells, the use of cell
compartment-specific inhibitors of JNK, namely, the JBD of
JIP1 fused to either nuclear exclusion or nuclear localization
sequences, also suggested a role for JNK activity outside the
nucleus (28). Further experiments will be required to support
the proposed pathway leading to effects on dendritic architec-
ture through microtubule-associated protein 2 phosphoryla-
tion by JNK. However, JNK1 has now been implicated in the
dendritic architecture of the cerebellum and motor cortex (28),
in addition to maintaining normal brain axonal growth (51)
and contributing to the repression of Wnt (Wnt-4 and Wnt-6)
expression and neural differentiation (as recently modeled in
embryonic stem cells) (10). It is therefore possible that a com-
plex range of JNK1 substrates regulates these biological pro-
cesses in vivo.
The microtubule-associated protein tau has also been shown
to be a substrate of JNKs (340). The phosphorylation of tau
reduces its ability to promote microtubule assembly (194), and
hyperphosphorylation inhibits binding to microtubules (32).
Thus, JNK-mediated phosphorylation of tau can be viewed as
inhibiting the actions of tau (Fig. 3). Nine sites for JNK
phosphorylation have been determined (340) (Table 3). This
phosphorylation has gained increasing interest due to its cor-
relation with abnormal filamentous inclusions of hyperphos-
phorylated tau in a range of neurodegenerative diseases, such
as Alzheimer’s disease (for a review, see reference 184). JNKs
are therefore possible targets to prevent hyperphosphorylation
of tau, and JNK inhibitors may prove useful in the treatment of
tauopathies. Furthermore, the amyloid  protein precursor has
also been shown to be phosphorylated by JNK, at Thr668
(Table 3), in a reaction facilitated by the JIP1 scaffold protein
(141, 170, 274). Interestingly, the scaffold protein JSAP1/JIP3
has been shown, in addition to JIP1, to cooperate with focal
adhesion kinase to regulate JNK and cell migration on fi-
bronectin (292). Thus, there are several layers of complexity
and specificity provided by this involvement of specific scaf-
folds.
The protein known as superior cervical ganglion 10
(SCG10), a stathmin-like family member, is a neuronal growth-
associated protein enriched in the growth cones of neurons
and is another substrate for JNK (242). SCG10 acts to de-
stabilize microtubules. JNK phosphorylation of SCG10 Ser62
and Ser73 (Table 3) reduces its microtubule-destabilizing ac-
tivity and provides a means for the control of growth cone
microtubule formation following the exposure of neurons to
stress (242) (Fig. 3). Although an interaction of JNK with
SCG10 comparable to the interaction of JNK with c-Jun has
been demonstrated (242) and although SCG10 can be purified
alongside other microtubule-destabilizing proteins, such as
SCG10-like protein or the stathmin-like proteins RB3 and
RB3	, or alongside other JNK-interacting proteins, such as
ATF2, -arrestin, or glutathione S-transferase  (297), no JBD
sequence has been reported for the SCG10 protein. While the
phosphorylation of Ser73 of SCG10 has been shown following
N-methyl D-aspartic acid receptor activation in the rat hip-
pocampus, a link to JNK activation has not been demonstrated
directly in this situation (228). However, SCG10 phosphoryla-
tion at Ser73 was depleted in the cortexes of brain tissues
isolated from jnk1
/
 animals, indicating a major role for the
JNK1 isoform in mediating SCG10 phosphorylation under
physiological conditions and suggesting that this is critical for
maintaining neuronal microtubule stability and efficient neu-
rite elongation (297).
The phenotypic changes of lissencephaly in males and ab-
normal neuronal positioning in females carrying mutations in
the X-linked gene DCX (78) have suggested a role for the
DCX gene product in neuronal migration. DCX is a microtu-
bule-associated protein that stabilizes microtubules through
interactions mediated by the evolutionarily conserved double-
cortin (DC) domain (168, 299). A link between neuronal mi-
gration and the JNK pathway was initially suggested by in-
creased JNK activity in radially migrating neurons in the
cerebral cortex and the ability of a dominant-negative JNK
mutant or the JNK inhibitor SP600125 to reduce migration
(159). JNK has been shown to phosphorylate the DCX protein
(105) (Table 3). The DC domains of DCX are required for
JNK-DCX interaction (105), although there is no sequence
similarity with the previously recognized docking motifs (295).
DCX was also shown to interact with the JNK scaffold protein
JIP1, suggesting the possible existence of a large JNK signaling
module in the brain (105). DCX mutants lacking the phosphor-
ylation site showed altered neuronal motility by a reduced
maximal velocity with prolonged stationary periods (105);
JNK-mediated phosphorylation of DCX can therefore be
viewed as activating DCX (Fig. 3). The interaction of JIP1 with
the motor protein kinesin (307) provides at least one addi-
tional point of regulation, localizing phosphorylated DCX to
neuron growth cones in a complex with JIP and JNK via the
interaction with kinesin (105). More recently, the kinesin heavy
chain was shown to be a substrate for JNKs (227). Although
the phosphorylation sites are not yet determined (Table 3), this
phosphorylation of kinesin inhibits its microtubule-binding ac-
tivity (Fig. 3); prevention of JNK activity appeared to reverse
the suppression of neurite formation by the polyglutamine-
expanded androgen receptor protein (227). This suggests that
targeting JNK may prove an important therapeutic strategy in
neurodegenerative disorders involving polyglutamine-ex-
panded protein.
The intermediate filament protein keratin 8 is also a JNK
substrate (127). The phosphorylation of intermediate filament
proteins has been suggested to affect their functional and as-
sembly states. Following the exposure of HT-29 cells to anti-
Fas receptor antibodies to activate this proapoptotic receptor,
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the phosphorylation of Ser73 from keratin 8 was observed to
show similar kinetics to the activation of JNK (127). Moreover,
a comparison of 32P-labeled keratin 8 immunoprecipitated
from cells with keratin 8 phosphorylated in vitro by JNK sup-
ported the conclusion that JNK phosphorylated this Ser resi-
due (Table 3). Furthermore, JNK and keratin 8 could be iso-
lated in coimmunoprecipitation experiments; however, the
residues involved in this interaction were not defined (127).
One possible consequence of JNK-mediated phosphorylation
of keratin 8 may be protecting the keratin network from cleav-
age by the proapoptotic proteases, i.e., the caspases (127),
although this possibility requires further testing.
GENERAL PRINCIPLES OF JNK SIGNALING VIA
PROTEIN PHOSPHORYLATION
JNK Peptide Specificity
The large range of protein substrates of JNK raises a num-
ber of interesting questions. First, we discuss the substrate
specificity of JNK. Specificity arises from the match between
the chemistries of the side chains of a bound peptide substrate
and specific pockets, or subsites, which are positioned between
the two lobes of the protein kinase (33). Molecular recognition
of the peptide sequence surrounding the phosphorylated resi-
due of a substrate is usually referred to as the “peptide spec-
ificity” of a protein kinase. The three-dimensional structures of
protein kinases with bound peptide substrates (34, 140, 172,
198, 335) have revealed that all three classes of protein kinases
bind their peptide substrates in an analogous manner, in an
extended conformation and with the same orientation of the
substrate peptide chain relative to the protein kinase (173). A
recent study has also shown the ability of protein kinase PKR
to induce a local unfolding of its substrate (eukaryotic trans-
lation initiation factor eIF2), specifically in the region of the
phosphorylated serine residue (69).
The distribution of the relative abilities of a protein kinase to
phosphorylate different peptide substrates falls sharply after a
small number of optimal peptides, and most peptide sequences
show negligible phosphorylation (353). However, peptide spec-
ificity is not the only element that determines the specificity of
phosphorylation in the cell; substrate recruitment plays a crit-
ical role in determining substrate preference. Substrate recruit-
ment is any process that can bring a kinase and a substrate in
close proximity, thus increasing the effective concentration of
the substrate and increasing the chance of forming the en-
zyme-substrate complex. The docking interactions common
in JNK substrates are a classical example of substrate recruit-
ment. The substrate preference is ultimately determined by the
combination of peptide specificity and recruitment. Recruit-
ment can have a significant effect on the phosphorylation of an
individual substrate, transforming a poor substrate into one
that can be effectively phosphorylated.
Inspection of the sequences surrounding JNK phosphoryla-
tion sites (Tables 1 and 3) reveals that almost any amino acid
is allowed in the positions surrounding the phosphorylated
Ser/Thr, with the exception of the position immediately C-
terminal to the phosphorylation site, which is restricted to Pro
(as discussed above). Tables 1 and 3 reveal four phosphory-
lated sequences that do not feature a Pro at this position
(instead featuring Phe, Leu, Ile, or Lys); in these cases, the lack
of Pro and the consequent unfavorable interaction must be
compensated for by other mechanisms, such as particularly
strong recruitment or specific structural features of the sub-
strate. The lack of apparent peptide specificity at other posi-
tions suggests a strong role for substrate recruitment in deter-
mining the substrate specificity of JNK.
If we use the substrate sequences in Tables 1 and 3 to
construct a consensus sequence for the heptapeptide surround-
ing the phosphorylated residue, they yield the sequence (S/A/
I/G/P/T/L/V)-(L/P/T/S/A)-(L/S/P/T/A/N/G)-(S/T)-(P)-(S/P/T/
E/L/G/A)-(S/L/A/P/R/E/K) (the residues shown are present in
5% of the substrates, and the residues shown in bold are
present in 10% of substrates). This consensus sequence is
similar to the structure-based optimal phosphorylation se-
quence prediction by Predikin (33), i.e., (L/I/M/F)-(P/T/A/S/
I)-(X)-(S/T)-P-(P/F/L/I/D/E)-(R/K/Q/S/L). All of the hep-
tapeptide substrate-binding residues are conserved among the
JNK isoforms; however, analysis of the three-dimensional
structure of JNK suggested that surface differences exist
among JNK isoforms that may affect substrate binding further
N-terminal (four or more residues away) from the phosphory-
lated residue (327).
To analyze whether the consensus sequence derived above
or the Predikin prediction could be used to predict new JNK
phosphorylation sites, we scored all heptapeptides surrounding
every Ser or Thr residue in the tau protein, using Scansite
(329), for their match to the JNK phosphorylation motifs (33).
The results indicated that using the consensus motif, the
known phosphorylation sites score 0.2228  0.0862 (minimum,
0.1383; maximum, 0.3457 [the lower the value, the closer the
match to the motif]), while the sites known to not be phosphor-
ylated score 0.3497  0.0670 (minimum, 0.1382; maximum,
0.4148). Using the motif predicted by Predikin, the corre-
sponding number for known phosphorylation sites is 0.2250 
0.0486 (minimum, 0.1306; maximum, 0.2612), while the sites
known to not be phosphorylated score 0.2859  0.0502 (min-
imum, 0.1306; maximum, 0.3266). These results indicate that
these motifs discriminate somewhat between phosphorylated
and nonphosphorylated sites, but there is substantial overlap
between the two distributions, and correspondingly, the prob-
ability of predictions is low. One can still use these predictions
to find the most likely phosphorylation sites in a protein that is
a known JNK substrate (Tables 1 and 3); such predictions can
direct mutagenesis experiments to confirm the phosphoryla-
tion sites.
Substrate Specificity of JNK Isoforms
In the preceding sections, only limited attention is given to
the role of the different JNK isoforms and their substrate
preferences. This is largely due to the lack of data, but there
are patterns emerging showing that different JNK isoforms,
despite their high levels of sequence similarity (reviewed in
reference 17), may show substrate preferences. Examples in-
clude the preferential interaction of JNK2, rather than JNK1,
with the substrate protein DCX (105) and the observation that
JNK2 phosphorylates a larger number of sites in tau and that
this is correlated with its ability to inhibit microtubule assembly
in vitro (340). JNK2 was identified as the ATFa-interacting
VOL. 70, 2006 JNK SUBSTRATE PROTEINS 1085
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
m
br.asm
.org/
D
ow
nloaded from
 
protein kinase (29), whereas JNK1 is a more efficient Itch
kinase than JNK2 (102).
Further clues are emerging with the use of cells lacking one
of the JNK isoforms (30). As an example, the use of jnk2-
deficient cells has suggested a role for JNK2, rather than
JNK1, in the inactivation of TIF-IA and subsequent downregu-
lation of rRNA synthesis (211). There may also be some de-
gree of isoform selectivity in JNK localization, with the report
of JNK2 translocation to the mitochondria in a PC12 model of
dopaminergic cell death (88). It will be critical to continue to
explore possible isoform-specific functions of JNKs within cells
and to be able to attribute these characteristics to differences in
substrate recognition by these kinases. Because of the high
sequence identities of the JNK isoforms and the broad peptide
specificity of JNKs, it is clear that a number of subtle mecha-
nisms (including transcriptional regulation, cellular localiza-
tion, and specific JNK-substrate interactions) must cooperate
in the cell to preferentially associate a JNK isoform with a
particular substrate.
Interplay of Phosphorylation by JNKs and Other
Protein Kinases
Because JNKs act within a broader intracellular signaling
network, it is also important to consider whether other kinases
phosphorylate the same or additional sites within JNK sub-
strate proteins. This has the potential to allow different kinases
to mediate similar effects in cells and to provide a means for
signal integration. There are many examples, but the following
cases illustrate the possible consequences in our understanding
of signal transduction. For the archetypical JNK substrate c-
Jun, other protein kinases can also catalyze the phosphoryla-
tion of Ser63 and Ser73. For example, the exposure of sympa-
thetic neurons in culture to the DNA-damaging agent
etoposide resulted in phosphorylation of both Ser63 and Ser73
and the subsequent upregulation of total c-Jun levels (25). The
inhibition of JNK activity or activation could not block either
the DNA damage-induced c-Jun phosphorylation or upregu-
lation or the subsequent death of these neurons (25). Instead,
pharmacological studies using olomoucine, roscovitine, flavo-
piridol, or alsterpaullone implicated either the CDKs or a
downstream kinase(s) of JNK. Therefore, these kinases, not
JNKs, would need to be targeted in further studies preventing
neuronal death after DNA damage (25). It will be interesting
to see whether inhibitors that target c-Jun itself will be more
effective in preventing neuronal cell death and whether such
substrate-directed inhibitors will be most effective when tar-
geting the substrate docking sites or the phosphorylation sites
themselves.
Other nuclear proteins are also subject to regulation by
phosphorylation at the same residues by different kinases. As
examples, JNK and p38 can both phosphorylate the same res-
idues of the transcription factor JPD2 (155), and JNK, ERK,
and p38 MAPKs can phosphorylate the transcription factor
Elk-1 (336). Interestingly, in Drosophila, the homologue of the
transcription factor ATF2 is involved in the response to UV
irradiation via p38 MAPK but not JNK (269). It is therefore
not sufficient to attribute actions to a stress-activated kinase
such as JNK without direct confirmation of its involvement. An
overlap of kinase functions is also seen in nonnuclear sub-
strates. Thus, the p38 family member SAPK4 (p38-) and
JNKs share many common phosphorylation sites on the mi-
crotubule-associated protein tau, and their actions are compa-
rable in inhibiting microtubule assembly in vitro (340). Simi-
larly, other MAPKs, such as ERK or the p38 family member
SAPK3 (p38-), glycogen synthase kinase 3, and CDK-5 can all
phosphorylate tau (21, 85, 111, 203), and both JNK and p38
appear to phosphorylate the same residue in Bax (166). mTOR
and JNK both phosphorylate Ser307 (133) and Ser318 (235) of
the adaptor protein IRS-1. The phosphorylation of the same
residues by different kinases emphasizes that effective targeting
strategies to prevent phosphorylation of critical signaling in-
termediates, such as IRS-1, will require a better understanding
of the role of specific kinases in phosphorylation reactions in
vivo and, additionally, that targeting the protein substrate may
provide interesting avenues for further investigation.
Many of the proteins phosphorylated by JNKs will also be
regulated by phosphorylation at additional sites by other
protein kinases. Even the archetypical JNK substrate, c-Jun,
is subjected to multisite phosphorylation by different kinases
(230), although the consequences of the different phosphor-
ylation sites on Jun function are not currently clear. An
interesting recent study (315) has shown that the phosphor-
ylation of c-Jun on Thr293 by glycogen synthase kinase 3
facilitates interaction with Fbw7 ubiquitin ligase in a man-
ner similar to that shown for JNK-mediated phosphoryla-
tion (240). Both lead to polyubiquitination of c-Jun and its
proteasomal degradation (315). Therefore, there is a critical
link between the two signaling pathways through Jun stabil-
ity and glycogen synthase kinase 3 activity. Importantly, this
example also highlights the importance of hierarchical phos-
phorylation; phosphorylation of Ser243 by a Pro-directed
kinase, such as ERK, is required before phosphorylation of
Thr293 by glycogen synthase kinase 3 can take place (315).
Therefore, the ultimate activation of a specific substrate
may require a number of signaling inputs.
For other proteins, studies of multisite phosphorylation have
revealed a number of interesting observations about signaling
complexity. Tyrosine phosphorylation of the JNK substrate
paxillin by c-Src allows its interaction with ERKs, thus provid-
ing new areas for cross talk and regulation by additional
MAPK family members (144). JNK-mediated phosphorylation
of the transcription factor ATF2 at Thr69 following insulin
stimulation follows ERK-mediated phosphorylation of ATF2
Thr71 (14). The JNK substrate TIF-IA is phosphorylated at
multiple sites by different protein kinases, such as mTOR and
ERK, which are required for TIF-IA activity and Pol I tran-
scription (212, 351). This contrasts with the negative regulation
of TIF-IA actions by JNK-mediated phosphorylation. Simi-
larly, the JNK substrate Itch is activated by JNK phosphoryla-
tion but negatively regulated by tyrosine phosphorylation me-
diated by Fyn (332). These examples emphasize that proteins
can be subjected to both positive and negative regulation by
phosphorylation at different sites. Conversely, the transactiva-
tion of p53 appears to be augmented by the activities of a
number of kinases acting together, and this may help to explain
why certain JNK activators, such as interleukin-1, do not sta-
bilize or activate p53 (239).
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Complexity of JNK Signaling
The enormous complexity of the response to JNK activation
has been illustrated by an evaluation of the JNK-dependent
responses of the human breast carcinoma BT474 cell line to
genotoxic shock following exposure to cisplatin. JNK has been
suggested to regulate DNA repair by transactivation of DNA
repair genes (125). Following phosphorylation of ATF2 and
c-Jun, a remarkable 269 of 3,083 gene promoters surveyed
showed increased binding of these transcription factors (126).
Treatment with the JNK inhibitor SP600125 decreased binding
of 98% of these genes in the cisplatin profile, confirming the
requirement for JNK activity in the response (126). The largest
functional group of upregulated genes consisted of 23 DNA
repair or repair-associated genes, 13 of which had not been
reported previously to be cisplatin sensitive or JNK regulated
(126). These 23 genes represent a large proportion of the 89
DNA repair genes represented on the array. Another major
group of upregulated genes included the immediate-early reg-
ulators of apoptosis (126). Interestingly, the application of
SP600125 in the absence of additional cisplatin stimulation
showed no major effect, thus suggesting that, at least under the
conditions of the study, there was a minimal contribution of
JNK to the regulation of these genes. The broader implications
of the study include the possibility that JNK/AP-1-mediated
resistance to chemotherapy by DNA-damaging drugs may be
effectively blocked by inhibition of one or more of the DNA
repair genes reported in the study.
A study evaluating JNK-regulated gene expression in rat
aortic vascular smooth muscle cells has also revealed a large
number of changes, particularly in a range of proteins involved
in proinflammatory signaling and extracellular matrix biosyn-
thetic pathways (343). Again, this observation has provided
new avenues for evaluation, and in this case, evidence was
presented supporting the use of JNK inhibitors as new thera-
peutic agents in the treatment of abdominal aortic aneurysm
(343). It will be interesting to see which transcription factor
substrates of JNK are the critical mediators of these responses
and whether there may be additional important roles for non-
transcription factor substrates.
The substrate repertoire of the JNKs may be increased
through the use of proteins such as scaffolds that tether sig-
naling modules. Figure 13 illustrates this general principle
alongside the direct recognition of substrates and the use of
substrate docking domains in substrate recognition. The use of
tethering proteins has been shown for the scaffold protein
JNK-associated leucine zipper protein (JLP), as originally
identified in the screening of a gt11 expression library of the
mouse myeloid cell line 32Dcl3 with the transcription factor
Max (180). In addition to containing two leucine zipper motifs,
JLP also showed similarity to the JSAP1/JIP3 scaffold proteins
of the JNK pathway, prompting an evaluation of the ability of
JLP to interact with other components of the MAPK pathway
(180). This analysis revealed that JLP could interact with JNK
or p38 MAPK but not with ERK2 (180). JNK and p38
MAPK appeared to interact with two distinct sites on JLP (JLP
residues 1 to 110 and JLP residues 160 to 209, respectively),
leading to the suggestion that JLP brings JNK and p38
MAPK signaling modules together (180). This was further
supported by data showing interactions of JLP with the up-
stream kinases MKK4 and MEKK3 as well as with the tran-
scription factor substrates c-Myc and Max (180). The scaffold-
ing function of JLP may therefore facilitate specific signaling to
c-Myc and Max while also preventing JNK phosphorylation of
other substrates (180). With the more recent identification of
kinesin light chain 1 as a binding partner for a leucine zipper
domain of JLP, it is possible that this motor protein will play a
critical role in the spatial regulation of this signaling module
(244).
CONCLUSIONS
In summary, our increased understanding of the substrates
of JNK is beginning to highlight the complexities involved in
intracellular signal transduction. Over 50 substrates have now
been identified for JNKs in the absence of any large-scale or
systematic screening strategy. It therefore seems likely that
many substrates still remain unknown and that JNKs may
phosphorylate more proteins than the estimated average of
40 substrates per kinase in humans (151). Improved methods
in protein kinase substrate identification (for reviews, see ref-
erences 24 and 173) should further aid our understanding of
how JNKs mediate their complex range of biological actions.
As discussed above, the phosphorylation of a particular sub-
strate by JNK, the identity of the phosphorylation site(s), and
the functional consequences of a phosphorylation event re-
main controversial in a number of cases. In some cases, these
proteins remain to be fully validated as JNK substrates. Several
criteria need to be met to identify a protein as a physiological
protein kinase substrate with reasonable confidence. These
criteria include (i) phosphorylation using purified proteins in
vitro with significant stoichiometry, (ii) phosphorylation in in-
tact cells in response to physiological stimuli at the same site as
that determined in vitro, (iii) stimulation of phosphorylation by
constitutively active kinase mutants, and (iv) inhibition of
phosphorylation of the substrate by dominant-negative forms
FIG. 13. Modes of substrate recognition by JNK. Active JNK ap-
pears likely to use at least three different modes of substrate recogni-
tion. For direct substrate recognition, the amino acids surrounding the
residue to be phosphorylated in the substrate protein are recognized at
the active site of the kinase. For both docking domain substrates and
scaffolded substrates, this requirement for direct substrate recognition
at the active site must also be fulfilled, but there are additional sites for
substrate recognition. A docking domain on the substrate itself may
enhance the interaction with the kinase, and similarly, the interaction
with a scaffold protein that can also interact with the kinase will also
increase the recognition of the substrate by the kinase.
VOL. 70, 2006 JNK SUBSTRATE PROTEINS 1087
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
m
br.asm
.org/
D
ow
nloaded from
 
of the kinase, by specific inhibitors, or in cells depleted of the
kinase (24). Indeed, the variability of sequences phosphory-
lated by JNK may be overestimated to some degree because of
the presence of incorrect phosphorylation sites.
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